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Figure 1: Taxonomy of mycobacteria; 128 different NTM were validly published by Euzeby’s in 2008.    
NTM = nontuberculous mycobacteria. The M. tuberculosis complex furthermore comprises M. canetti, 
M. orygis, M. bovis BCG, M. pinnipedii, M. mungi, and M. microti
Mycobacteria
The genus Mycobacterium can be  divided in three groups;  Mycobacterium tuberculosis 
complex, M. leprae and the nontuberculous mycobacteria (NTM) (Figure 1). M. tuberculosis 
complex and M. leprae cause disease (tuberculosis and leprosy) in healthy immunocompe-
tent individuals; NTM are opportunistic pathogens.1 NTM are also known as environmental 
mycobacteria due to their widespread presence in, for example, water and soil. NTM disease 
most commonly presents at pulmonary sites  in humans. Chronic obstructive pulmonary dis-
ease (COPD) and bronchiectasis are important pre-existing conditions and known risk factors 
for NTM pulmonary disease.2-5 NTM are also known to cause disseminated disease in immu-
nocompromised hosts, including patients with HIV, haematological malignancies, solid organ 
transplants, and those with inherited immune disorders.2 Human transmission of NTM has 
never been proven. This is an important epidemiological difference compared to mycobac-
teria belonging to the Mycobacterium tuberculosis complex. The total number of identified 
and officially recognised NTM species is increasing. This increase is probably mainly due to 
improved laboratory techniques, especially molecular identification techniques. In 2008, 128 
different species had been published (http://www.bacterio.cict.fr/m/mycobacterium.html). 
Improved knowledge of the divergence among the NTM species is important to improve un-
derstanding of the epidemiology and pathogenesis of disease caused by NTM.
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1Mycobacteria: from bacteriology to clinical diseaseNTM have been recognized as different mycobacteria not long after Robert Koch discovered 
Mycobacterium tuberculosis in 1882. Mycobacteria isolated from the environment, but 
also from animals were indicated as atypical M. tuberculosis. These atypical, or anonymous 
mycobacteria were divided by Runyon, in 1959, in four groups based on their pigmentation 
after light exposition and grow rate: (1) photochromogens, i.e. those producing a pigment 
of exposition to light, slow growing; (2) scotochromogens, i.e. those producing pigment 
irrespective of light exposure, slow growing; (3) non-chromogens, i.e. those not producing 
pigments, slow growing and (4) rapidly growing mycobacteria (i.e. growth in <7 days from 
subculture).6 After the discovery of NTM, it took almost 50 years until the first large case series 
were published related to pulmonary disease caused by these mycobacteria.7-12 Buhler and 
Polack identified a ‘yellow bacillus’ that was capable of causing tuberculosis-like disease in 
humans in the 1950s.7 This bacillus produced a yellow pigment after exposure to light, hence 
its name. This Mycobacterium is now known as M. kansasii. Other NTM were identified, based 
on differences in their phenotypic properties and growth rates that were capable of causing 
chronic pulmonary disease. It became clear that NTM disease showed some important 
epidemiological differences with tuberculosis. In a retrospective case-control study by Kamat 
1961,9 57 patients with NTM isolates were compared with 57 tuberculosis patients. Miners 
were significantly more represented in the NTM group than in the tuberculosis group. Also 
the NTM patients had significantly more pneumoconiosis on chest X-ray examination. 
Furthermore, patients with NTM were found to be of older age and more common of the 
Caucasian race compared to tuberculosis patients. In a large retrospective epidemiologic 
survey, NTM pulmonary disease was found more commonly among the low socio-economic 
stratum.13 Although not systematically recorded, Kamat reported chronic bronchitis and 
emphysema as commonly mentioned in the medical files of the NTM group. Pneumoconiosis 
and chronic obstructive pulmonary disease (COPD) among middle aged male patients were 
from then consistently reported in case series. Wolinsky described the average NTM case to 
be a middle-aged white man with long standing lung disease, such as COPD or silicosis, who 
presents with a 3-month history of productive cough, night sweats, moderate weight loss, 
low grade fever, and a chest roentgenogram with upper-lobe cavitation (Figure 2A).1 
Pre-existing lung disease including COPD and bronchiectasis are still associated with NTM 
pulmonary disease.2-5 NTM disease in patients with pre-existing pulmonary disease, especially 
COPD, is likely the most frequent NTM disease entity worldwide. However, little is known 
about the pathologic background of COPD –or other underlying lung diseases- and the 
association with NTM pulmonary disease. For example, there is no evidence of an influence 
of NTM isolation/disease on COPD exacerbations or disease progression. 
 
In the late 1980s a case series was published describing 21 patients, of whom 17 were 
females, with M. avium complex (MAC) lung disease without any apparent underlying 
(pulmonary) disease.14 Bronchiectasis and nodular abnormalities, especially affecting the 
lingula or middle lob, were the radiographic abnormalities seen in this patient group (Figure 
2B). Reich and Johnson15 later described the same category of patients and hypothesized 
that these women could have had the habit of voluntary suppression of cough, responsible 
for the inability to clear the secretions from the lingula and middle lobe. This habit results 
in a focus of inflammation in these areas, which in turn predisposes to MAC infection. They 
named this condition Lady Windermere syndrome after Oscar Wilde's Victorian-era play Lady 
Windermere's Fan to suggest the fastidious behavior. Recently, it was found that a genetic 
background is more likely to be responsible based on an associated body habitus (scoliosis, 
pectus excavatum, and mitral valve prolaps), together with more frequently found mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) in these women. 
Hypersensitivity pneumonitis is another form of pulmonary NTM disease, also called hot-
tub lung since aerosols from hot-tubs containing NTM (mainly M. avium complex) cause an 
inflammatory reaction in the lung.16 Non-necrotizing granulomas are found in lung tissue of 
these patients. More recently, pulmonary NTM disease emerged as a severe and possibly 
emerging opportunistic infection in cystic fibrosis (CF) patients. MAC and M. abscessus are 
the most important causative agents of NTM disease in CF patients, the latter most frequently 
isolated in Europe.17-19 
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Figure 2: Radiographic abnormalities seen in NTM pulmonary disease. 
                A: upper lobe cavitation; 
                B: nodular-bronchiectatic disease.
During the HIV epidemic, NTM (especially M. avium complex and M. kansasii) were increasingly 
recognised as causing  disseminated disease , especially among patients with low CD4 counts 
(below 50 cells/µL).20-21 Other recognized risk groups for NTM disseminated disease were 
patients with other forms of immunosuppression (caused by drugs or certain disease states, 
i.e. hematologic malignancies) (Table 1).
Cervical lymphadenitis caused by NTM is an important disease entity seen in children aged 
below 9 years of age. Lymph node involvement is a form of extra-pulmonary disease, and 
interestingly not associated with immunosuppressive disorders. In developed countries, NTM 
cervical lymphadenitis is more commonly observed than tuberculosis lymphadenitis.22
Other forms of localised, extra-pulmonary NTM disease are NTM infections of skin, soft tissue 
and bone. Skin infections after skin wounds or in tattoos are most common in which M. 
marinum and rapid growing mycobacteria are frequently the causative agents.2, 23  In rain 
forest areas, M. ulcerans is frequently encountered as the pathogen causing serious and 
treatment resistant necrotic lesions.24
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American Thoracic Society Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan that shows multifocal 
bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. (If the results from the initial 
sputum samples are nondiagnostic, consider repeat sputum AFB smears and cultures.)
Box 1: Summary of the 2007 American Thoracic Society diagnostic criteria2 
Abbreviations: CT = Computed tomography, HRCT = High resolution computed tomography 
NTM disease 
location Clinical disease Common causative NTM Predisposing conditions
Pulmonary
Cavitary disease MAC, M. malmoense, M. 
kansasii
COPD
Nodular-bronchiectatic
(lingular or middle lobe 
predominance)
MAC, M. abscessus CF
Female patients
 Hypersensitivity 
pneumonitis
MAC, M. immunogenum
Extra-pulmonary
Cervical lymphadenitis MAC, M. haemophilum, M. 
malmoense
Children
Skin, soft tissue and bone 
infections
M. marinum, M. ulcerans, 
RGM Wounds, tattoos, trauma 
Disseminated Bone marrow, liver, blood, 
skin
MAC, M. kansasii, M. 
genavense, RGM (skin)
HIV, immunosuppressive 
drugs, malignancies
MAC = M. avium complex, COPD = chronic obstructive pulmonary disease, CF = cystic fibrosis, 
RGM = rapid growing mycobacteria
Table 1: NTM disease characteristics
1
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Epidemiology and global aspects of NTM isolation
The epidemiology of NTM disease is difficult to assess since most of the studies available 
are based on voluntary reporting of NTM isolation. A great number of studies reported the 
frequencies of NTM isolation rather than the number of patients with true NTM disease. 
Epidemiological data regarding the number of patients with NTM disease are expected to be 
lower compared to epidemiological data concerning patients from whom a NTM has been 
isolated (see the Diagnosis of NTM disease).
Marras and Daley25 reviewed the literature on epidemiology of pulmonary NTM isolation and 
disease. They identified several studies worldwide that showed an increase in pulmonary 
NTM isolation and disease together with a decrease in tuberculosis incidence, a trend 
that started soon after the introduction of successful chemotherapy for tuberculosis. NTM 
disease prevalence in North America was found to vary between 0.1-2/100.000. In specific 
populations, such as mine workers, extremely high rates of NTM disease were found for 
example in the Czech republic and South Africa (up to 78/100.000). In Queensland, Australia, 
NTM isolation is a condition that needs to be formally notified. This gives more representative 
information on NTM isolation and disease for this region. In a recent study from Australia, 
an increase in the prevalence of clinical relevant NTM pulmonary disease was observed of 
2.2/100.000 in 1999 and 3.2/100.000 in 2005.26 In Ontario, Canada, isolation prevalence 
increased significantly between 1997 and 2003.27 A recent study from the United States 
found a minimum prevalence rate of pulmonary NTM disease of 8.6/100.000 in the general 
population.28 In elderly subjects this figure rises to a minimum of 20.4/100.000. If these 
figures are representative for developed countries than NTM pulmonary disease is nowadays 
a larger health threat than pulmonary tuberculosis. However, these figures are far above the 
estimated NTM disease incidence of 1.7/100.000 in the Netherlands in 2008.29 
Isolation frequencies of different NTM species depend on the area studied.25, 30 Although MAC 
is the most common NTM isolated worldwide, in some areas other NTM are the predominant 
NTM isolated, and after MAC, the variation in isolation frequency differs significantly. In 
the Czech Republic and Turkey, M. kansasii and M. fortuitum were the most predominant 
NTM isolated, respectively.30 In South Africa, M. kansasii was observed to be predominant 
among mine workers.31 Since NTM isolation and disease is increasing in many countries, 
together with the observation that NTM isolation can differ between regions and countries, 
epidemiological studies remain important to understand and monitor NTM disease. A 
thorough understanding of NTM isolation and disease, together with information regarding 
differences in geographical isolation, may enhance knowledge about risk factors associated 
with NTM transmission to humans and thus prevention of NTM disease. 
Diagnosis of NTM disease
The diagnosis of NTM disease is a challenge. Because of the environmental nature of the 
NTM, isolation of NTM from normally non-sterile sources, mainly the respiratory tract, has 
to be related to clinical and radiographic data to distinguish true mycobacterial disease 
from contamination from an environmental source. This contamination likely reflects 
occasional presence of NTM in the airways after environmental exposure which lasts 
until the NTM are either neutralized by the immune system or mechanically removed by 
11
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sputum expectoration.32 33 Contamination can also be the result of, for example, laboratory 
procedures or contamination of bronchoscopes via bronchoscope washers, as well as 
sputum contamination because of tap water mouth rinsing prior to sputum expectoration.32 
33 The distinction between contamination and true infection is important, since diagnosis of 
infection with an NTM -correct or incorrect- may lead to a long period of treatment with anti-
mycobacterial drugs.  In the 1950s, Runyon proposed criteria for diagnosis of NTM disease.6 
At that time, the widespread environmental nature of the NTM, and thus the possibility of 
contamination was not clearly recognized. However, criteria were established because of 
the observation that, in contrast to tuberculosis, NTM isolation from respiratory specimens 
was not always related to clinical disease. One of the first proposed diagnostic criteria that 
incorporated clinical data and microbiological criteria was published by Ahn and co-workers 
in 1982, based on a cohort of 271 patients with M. kansasii isolates and 226 patients with 
MAC.34 It was stated that colonization is an important issue to be considered, especially in 
patients with pre-existent chronic respiratory diseases and multiple NTM isolates but without 
cavitary lesions. Airway hygiene in these patient groups (with or without a short course of 
anti-mycobacterial drug therapy) often showed to be sufficient to clear the NTM from the 
airways. 
The first American Thoracic Society (ATS) statement on NTM pulmonary disease was published 
in 1990 and incorporated clinical criteria as well.35 For cavitary lesions , clinical relevant NTM 
isolation was considered to be present when (1) two or more sputa are acid-fast bacilli smear-
positive and/or result in moderate to heavy growth of NTM on culture and (2) other diseases 
have been excluded. In 1997, a revised ATS statement was published in which the criteria for 
non-cavitary isolation were deleted since the increased use of computed tomography (CT) 
scanning revealed that multiple NTM isolation is often related to other lesions related to NTM 
pulmonary disease not seen on a conventional chest radiograph (i.e. nodular-bronchiectatic 
lung disease).36 Colonization of NTM was believed to be uncommon. Fibrocavitary NTM 
pulmonary disease on one hand, and nodular-bronchiectatic disease on the other hand (Figures 
2A and 2B) are still important in the most recently ATS criteria on NTM disease published in 
2007 (Box 1).2 The bacteriologic criteria in the previous statements were not supported by 
scientific evidence; the microbiological criteria in the current guideline are supported by one 
study. In this landmark study, Michio Tsukamura demonstrated that radiologic evidence of 
disease (infiltrates or cavitary lesions) and progression was found in 98% of the patients who 
had two or more positive sputum cultures for M. avium complex, compared to just 2% in 
those with a single positive culture during 12 months of observation. For 97% of patients, the 
first two positive cultures grew from the initial three sputum specimens.37 The microbiological 
criteria are more difficult to apply to nodular-bronchiectatic disease because not all patients 
produce sputum and bacterial loads in sputum are generally lower than in cavitary disease.2
Treatment of NTM disease 
Even if a diagnosis of NTM disease is made, the decision to start treatment creates a moment 
of weighing several arguments. Co-morbidity and resulting drug use, alcohol abuse and 
severe weight loss interfere with the toxic antimycobacterial drugs that generally have to 
be taken for at least 18 months depending on the NTM species and type of disease.2 In 
addition, because of a lack of clinical trials, doubts about clinical efficacy often prevents or 
delays the initiation of antimycobacterial  drug treatment. These doubts are understandable, 
as relapses and treatment failures are frequent in studies of treatment outcome, especially 
in pulmonary NTM disease.38 The first randomised clinical trial concerning NTM pulmonary 
disease was published in 2001 by the British Thoracic Society (BTS).38 Patients with MAC, M. 
xenopi, and M. malmoense pulmonary disease were randomised between rifampicin plus 
ethambutol (RMP + EMB), and RMP/EMB plus isoniazid (INH). Failure and relapse rates were 
lower in the RMP/EMB/INH-group for patients with MAC disease, but RMP/EMB/INH was 
associated with increased mycobacterial disease related death for all three species combined. 
Outcome figures at five years showed a 33% cure rate for all species combined, 17% failure 
of treatment or relapse, and a 33% all-cause mortality rate. In 2008, the next comparative 
trial was published by the BTS: a RMP/EMB regimen combined with either ciprofloxacin or 
clarithromycin was not superior to the observed outcome of RMP/EMB only in the previous 
BTS trial for the species studied combined (MAC, M. malmoense, M. xenopi).39 However, for 
MAC, relapse rates were lower for RMP/EMB plus clarithromycin compared to RMP/EMB plus 
ciprofloxacin. Furthermore, while the relapse rate of RMP/EMB was found to be 41% in the 
first BTS trial, RMP/EMB plus clarithromycin showed a relapse rate of 13%. These results are 
in line with previous observational studies performed in the US in which clarithromycin was 
found to be effective against MAC pulmonary disease, yielding sputum culture conversion 
rates of 92% at 12 months follow-up after completion of at least 6 months of a clarithromycin 
based multi-drug regimen.40 Tanaka and colleagues revealed that culture conversion rate of 
the triple drug regimens RMP/EMB and a macrolide with adjunctive aminoglycosides during 
the first months of therapy was 71.8% overall.41 In patients with MAC isolates that showed 
clarithromycin resistance, poorer sputum conversion rates were observed in both studies. 
Drug susceptibility testing is useful for MAC lung disease (with only clarithromycin 
susceptibility predicting treatment outcome in these patients), in M. kansasii disease (RMP 
resistance), and in disease caused by some of the rapid growing mycobacteria.42 Since in 
vitro drug susceptibility of other species, or of drugs other than clarithromycin and rifampicin 
for MAC and M. kansasii respectively, has never been correlated with clinical outcome, the 
interpretation of drug susceptibility testing should be made with caution.
The outcomes of treatment differs strongly by species Outcomes are favourable in M. 
kansasii disease, with long term culture conversion rates up to 100%43-45; outcomes are poor 
in pulmonary disease caused by e.g. the rapid grower M. abscessus at only 28%.46 In general, 
there are few clinical trials and thus randomized controlled trials are needed including new 
drugs and drug combinations.47 In addition to adequate chemotherapy, surgery may be 
considered in all patients with localized pulmonary NTM disease as it is known to improve 
sputum conversion rates in selected patient groups.46, 48 Surgical resection in patients for whom 
drug treatment is unlikely to be successful, e.g. those with M. abscessus disease will benefit 
from surgery especially.2 However, only a minority of patients have NTM pulmonary disease 
suitable for surgery. Since outcome of surgical intervention is found to be inversely related 
to local experience with NTM surgery, referral to an expertise center is strongly advised.49 
Whether treatment with airway clearance interventions (bronchodilators, mucolytics, 
mechanical aids such as oscillatory positive expiratory pressure devices) are as effective as in 
non-CF bronchiectasis has to be addressed in future studies.
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Research questions and thesis outline
Research of the epidemiology of NTM isolation and disease must have priority on the agenda. 
In clinical practice, isolation of NTM frequently raises questions about the association of NTM 
isolation and clinical symptoms. Sputum samples are generally taken because of (change in) 
clinical symptoms and signs related to the underlying condition itself rather than to myco-
bacterial disease which make interpretation even more difficult. In this thesis the focus is on 
NTM epidemiology, pulmonary NTM isolation, clinical relevance, and NTM disease.
Chapter 2 focuses on geographical aspects of pulmonary NTM isolation. Physicians are in-
creasingly confronted with NTM isolates and the difficult task of establishing their clinical sig-
nificance in individual patients. The scientific literature is of limited help , as both the species 
distribution and their clinical relevance seem to differ by geographical area. In this chapter 
the goal is to give a snapshot of worldwide pulmonary NTM isolation. Gaining knowledge on 
NTM species distribution can help in identifying factors associated with human NTM infec-
tion like climate differences, population density, or host factors. The epidemiology of NTM 
isolation in the Netherlands is studied in more detail in chapter 3. This study was carried out 
especially to explore the factors, other than improved laboratory techniques, associated with 
the observed increase in NTM isolation in the Netherlands. 
In chapter 4 a prospective cohort study is described in which patients presenting with an 
acute exacerbation of COPD are screened for NTM in their sputum. COPD is a well-known risk 
factor for NTM disease, however, little is known about the pathogenesis of NTM isolation and 
disease in this patient group. The question raised in this study is whether NTM can be isolated 
from a COPD patient without clinical signs of NTM disease and to explore the possible risk 
factors of this NTM presence. 
In chapter 5-7, we focus on M. malmoense, a NTM species strongly associated with clinical 
(pulmonary) disease in humans in The Netherlands. First, in chapter 5, we review the litera-
ture on epidemiology, clinical relevance, treatment, and outcome of M. malmoense world-
wide. Because of the observed rise in incidence of M. malmoense isolation in recent years, 
together with a high percentage of patients showing definite clinical M. malmoense disease 
in Northern Europe, we performed a retrospective medical file study for all known M. mal-
moense isolates received at the national mycobacterial reference laboratory in the Nether-
lands; the National institute for Public Health and the Environment (RIVM) (chapter 6). 
In this study, we identified two patients with strong epidemiological links and pulmonary M. 
malmoense disease in whom we studied the possible inter-human transmission of the caus-
ative M. malmoense strain (chapter 7). 
We have reviewed the NTM database of the RIVM and observed that the infrequently iso-
lated NTM M. genavense, especially known to cause disseminated disease in HIV positive pa-
tients with low CD4 counts, was isolated especially from sterile body sites like bone marrow 
and liver. In this era of successful HIV treatment, we expected a change in its epidemiology 
and etiology, which had  not been studied in detail before. In chapter 8, we reviewed the 
medical files of all patients with M. genavense disease in the RIVM database to determine 
clinical relevance, predisposing conditions, treatment, and outcome.
14
Chapter 1
1. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979: 119(1): 107-159.
2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G,   
    Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr., Winthrop K. An official ATS/IDSA   
 statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. 
 Am J Respir Crit Care Med 2007: 175(4): 367-416.
3. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical   
 relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. 
 Thorax 2009: 64(6): 502-506.
4. Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW. Chronic respiratory disease, inhaled  
 corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013: 68(3): 256-262.
5. Fowler SJ, French J, Screaton NJ, Foweraker J, Condliffe A, Haworth CS, Exley AR, Bilton D. Nontuberculous   
 mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J 2006: 28(6): 1204-1210.
6. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 1959: 43(1): 273-290.
7. Buhler VB, Pollak A. Human infection with atypical acid-fast organisms; report of two cases with pathologic   
 findings. Am J Clin Pathol 1953: 23(4): 363-374.
8. Wood LE, Buhler VB, Pollak A. Human infection with the yellow acid-fast bacillus; a report of fifteen additional  
 cases. Am Rev Tuberc 1956: 73(6): 917-929.
9. Kamat SR, Rossiter CE, Gilson JC. A retrospective clinical study of pulmonary disease due to "anonymous   
 mycobacteria" in Wales. Thorax 1961: 16: 297-308.
10. Crow HE, King CT, Smith CE, Corpe RF, Stergus I. A limited clinical, pathologic, and epidemiologic study of   
 patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum. 
 Am Rev Tuberc 1957:75(2): 199-222.
11. Lewis AG, Jr., Lasche EM, Armstrong AL, Dunbar FP. A clinical study of the chronic lung disease due to   
 nonphotochromogenic acid-fast bacilli. Ann Intern Med 1960: 53: 273-285.
12. Timpe A, Runyon EH. The relationship of atypical acid-fast bacteria to human disease; a preliminary report. 
 J Lab Clin Med 1954: 44(2): 202-209.
13. Prather EC, Bond JO, Hartwig EC, Dunbar FP. Preliminary report: epidemiology of infections due to the atypical  
 acid-fast bacilli. Dis Chest 1961: 39: 129-139.
14. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, Figueroa WG, Fish JE. Infection with   
 Mycobacterium avium complex in patients without predisposing conditions. 
 N Engl J Med 1989: 321(13): 863-868.
15. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or  
 middle lobe pattern. The Lady Windermere syndrome. Chest 1992: 101(6): 1605-1609.
16. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect 2003: 18(1): 33-39.
References 
15
General introduction
References 1
17. Olivier KN, Weber DJ, Wallace RJ, Jr., Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW,   
 Schechter MS, Edwards LJ, Chakraborti S, Knowles MR. Nontuberculous mycobacteria. I: multicenter   
 prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003: 167(6): 828-834.
18. Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le Roux E, Lemonnier L,  
 Gutierrez C, Vincent V, Fauroux B, Rottman M, Guillemot D, Gaillard JL, Jean-Louis Herrmann for the OMAG.   
 Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. 
 J Clin Microbiol 2009: 47(12): 4124-4128.
19. Verregghen M, Heijerman HG, Reijers M, van Ingen J, van der Ent CK. Risk factors for Mycobacterium   
 abscessus infection in cystic fibrosis patients; a case-control study. J Cyst Fibros 2012: 11(4): 340-343.
20. Horsburgh CR, Jr., Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the  
 acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989: 139(1): 4-7.
21. Kalayjian RC, Toossi Z, Tomashefski JF, Jr., Carey JT, Ross JA, Tomford JW, Blinkhorn RJ, Jr. Pulmonary disease due  
 to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1995: 20(5): 1186-1194.
22. Haverkamp MH, Arend SM, Lindeboom JA, Hartwig NG, van Dissel JT. Nontuberculous mycobacterial infection  
 in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004: 39(4): 450-456.
23. LeBlanc PM, Hollinger KA, Klontz KC. Tattoo ink-related infections--awareness, diagnosis, reporting, and   
 prevention. N Engl J Med 2012: 367(11): 985-987.
24. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, Wansbrough-Jones MH, Johnson PD,  
 Portaels F, van der Graaf WT, Asiedu K. Mycobacterium ulcerans disease. 
 Bull World Health Organ 2005: 83(10):785-791.
25. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. 
 Clin Chest Med 2002: 23(3): 553-567.
26. Thomson RM, Centre NTMwgaQTC, Queensland Mycobacterial Reference L. Changing epidemiology of   
 pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010: 16(10): 1576-1583.
27. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria  
 in Ontario, 1997 2003. Thorax 2007: 62(8): 661-666.
28. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary  
 nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. 
 Am J Respir Crit Care Med 2010: 182(7): 977-982.
29. van Ingen J. Nontuberculous Mycobacteria: from gene sequences to clinical relevance. Nijmegen: Radboud   
 University Nijmegen; 2009.
30. Martin-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K,   
 Havelkova M, Katila ML, Koksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rusch-Gerdes S,  
 Tortoli E, Vincent V, Watt B, Spanish Group for Non-Tuberculosis M. Non-tuberculous mycobacteria: patterns of  
 isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004: 8(10): 1186-1193.
31. Corbett EL, Churchyard GJ, Clayton T, Herselman P, Williams B, Hayes R, Mulder D, De Cock KM. Risk factors for  
 pulmonary mycobacterial disease in South African gold miners. A case-control study. 
 Am J Respir Crit Care Med 1999: 159(1): 94-99.
32. Kressel AB, Kidd F. Pseudo-outbreak of Mycobacterium chelonae and Methylobacterium mesophilicum caused  
 by contamination of an automated endoscopy washer. Infect Control Hosp Epidemiol 2001: 22(7): 414-418.
33. Lai KK, Brown BA, Westerling JA, Fontecchio SA, Zhang Y, Wallace RJ, Jr. Long-term laboratory contamination by  
 Mycobacterium abscessus resulting in two pseudo-outbreaks: recognition with use of random amplified   
 polymorphic DNA (RAPD) polymerase chain reaction. Clin Infect Dis 1998: 27(1): 169-175.
34. Ahn CH, McLarty JW, Ahn SS, Ahn SI, Hurst GA. Diagnostic criteria for pulmonary disease caused by   
 Mycobacterium kansasii and Mycobacterium intracellulare.  Am Rev Respir Dis 1982: 125(4): 388-391.
35. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. 
 Am Rev Respir Dis 1990: 142(4): 940-953.
36. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the   
 American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the   
 American Lung Association. Am J Respir Crit Care Med 1997: 156(2 Pt 2): S1-25.
37. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991: 99(3): 667-669.
38. Society RCotBT. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare,  
 M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin 
 and ethambutol. Thorax 2001: 56(3): 167-172.
39. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts  
 to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of   
 Mycobacterium  vaccae immunotherapy. Thorax 2008: 63(7): 627-634.
40. Wallace RJ, Jr., Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary   
 Mycobacterium avium complex. The first 50 patients. 
 Am J Respir Crit Care Med 1996: 153(6 Pt 1): 1766-1772.
41. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F.  
 Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. 
 Am J Respir Crit Care Med 1999: 160(3): 866-872.
42. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of  
 nontuberculous mycobacteria. Drug Resist Updat 2012: 15(3): 149-161.  
43. Shitrit D, Baum GL, Priess R, Lavy A, Shitrit AB, Raz M, Shlomi D, Daniele B, Kramer MR. Pulmonary   
 Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. 
 Chest 2006: 129(3): 771-776.
44. Ahn CH, Lowell JR, Ahn SS, Ahn S, Hurst GA. Chemotherapy for pulmonary disease due to Mycobacterium   
 kansasii: efficacies of some individual drugs. Rev Infect Dis 1981: 3(5): 1028-1034.
16
Chapter 1
References 
17
General introduction
References 1
45. Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by   
 Mycobacterium kansasii. Am Rev Respir Dis 1983: 128(6): 1048-1050.
46. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients   
 receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011: 52(5): 565-571.
47. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and  
 amikacin in treatment of nontuberculous mycobacterial disease. 
 Antimicrob Agents Chemother 2012: 56(12): 6324-6327.
48. van Ingen J, Verhagen AF, Dekhuijzen PN, van Soolingen D, Magis-Escurra C, Boeree MJ, de Lange WC. Surgical  
 treatment of non-tuberculous mycobacterial lung disease: strike in time. 
 Int J Tuberc Lung Dis 2010: 14(1): 99-105.
49. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous   
 mycobacterial disease. Ann Thorac Surg 2008: 85(6): 1887-1892.
18
The geographic diversity of nontuberculous 
mycobacteria isolated from pulmonary 
samples:
A NTM-NET collaborative study
19
2Chapter 
W. Hoefsloot, J. van Ingen, C. Andrejak, K. Ängeby, R. Bauriaud, P. Bemer, N. Beylis, M.J. Boeree, J. Cacho , V. 
Chihota, E. Chimara, G. Churchyard, R. Cias, R. Dasa, C.L. Daley, P.N.R. Dekhuijzen, D. Domingo, F. Drobniewski, J. 
Esteban, M. Fauville-Dufaux, D.B. Folkvardsen, N. Gibbons, E. Gómez-Mampaso , R. Gonzalez , H. Hoffmann, P.R. 
Hsueh, A. Indra, T. Jagielski, F. Jamieson, M. Jankovic, E. Jong, J. Keane, W.J. Koh, B. Lange, S. Leao, R. Macedo, T. 
Mannsåker, T.K. Marras, J. Maugein,  H.J. Milburn, T. Mlinkó, N. Morcillo, K. Morimoto, D. Papaventsis, E. Palenque, 
M. Paez-Peña, C. Piersimoni, M. Polanová, N. Rastogi, E. Richter, M.J. Ruiz-Serrano, A. Silva, M.P. da Silva, H. Simsek, 
D. van Soolingen, N. Szabó, R. Thomson, M.T. Tórtola Fernandez, E. Tortoli, S.E. Totten, G. Tyrrell, T. Vasankari, M. 
Villar, R. Walkiewicz, K. Winthrop, D. Wagner for NTM-NET (www.ntm-net.org).
Eur Respir J 2013; erj01492-2012; published ahead of print.
20
Chapter 2
Abstract
A significant knowledge gap exists concerning the geographical distribution of nontuberculous 
mycobacteria (NTM) isolation worldwide. 
To provide a snapshot of NTM species distribution, global partners in the NTM-NET framework 
(www.ntm-net.org), a branch of TBNET, provided identification results of the total number of 
patients in 2008 in whom NTM were isolated from pulmonary samples. From these data, we 
visualized the relative distribution of the different NTM found per continent and country.
We received species identification data for 20182 patients, from 62 laboratories in 30 countries 
across six continents. Ninety-one different NTM species were isolated. Mycobacterium avium 
complex (MAC) bacteria predominated in most countries, followed by M. gordonae and 
M. xenopi. Important differences in geographical distribution of MAC species as well as M. 
xenopi, M. kansasii, and rapid growing mycobacteria were observed.
This snapshot demonstrates that the species distribution among NTM isolates from pulmonary 
specimens in the year 2008 differed by continent and differs by countries within these 
continents. These differences in species distribution may partly determine the frequency and 
manifestations of pulmonary NTM disease in each geographical location.
21
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples
2
Introduction
Disease caused by nontuberculous mycobacteria (NTM) has gained increased attention, in 
part because of an assumed increase in its incidence.1,2 With the emergence of case reports 
and series from diverse countries and regions, it has become clear that the distribution 
of NTM species that are isolated from clinical samples differs strongly by region.3 Yet, this 
geographic diversity has never been systemically studied. Increased understanding of this 
diversity is important, as it can provide important clues on the impact of geographical or 
climatic differences on NTM distribution and observed discrepancies in clinical relevance 
and treatment outcome.3,4 In this study we have collected pulmonary NTM isolation and 
identification results from laboratories in different regions in the world, collaborating within 
the NTM-NET network (www.ntm-net.org, a branch of TBNET), from the same time period, to 
gain further insight on the geographical distribution of NTM species cultured from respiratory 
samples at a single time point.
Methods
Global partners in the NTM-NET framework were contacted and invited to provide data 
of the total number of patients from whom NTM were isolated from pulmonary samples 
in their hospital, regional or reference laboratory in the year 2008, as well as the species 
identification results and details of the identification methods used. Partners were eligible 
to contribute to the database if the number of patients with pulmonary NTM isolates per 
year exceeded 30 to ensure sufficient experience and interpretability of results; one isolate 
per species per patient was eligible for analysis. We have chosen pulmonary samples in an 
effort to minimize selection bias. Isolation of NTM from normally sterile sites such as blood or 
lymph nodes usually indicates definite disease and this may present a strong selection bias, 
as not all species are equally capable of causing such diseases.
We calculated total number of mycobacteria per continent, the relative contribution of the 
Mycobacterium avium complex for each continent or country, and studied the differences in 
the relative contribution of other NTM between countries and continents by generating pie-
charts. Data of the respondents were plotted on a world map. Since most NTM-NET members 
are located in Europe, data from European participants were assessed in greater detail, with 
a focus on north-south differences; we considered Denmark, Norway, Sweden, Finland, 
the Netherlands, Belgium, Germany, England, Ireland and Poland as Northern Europe; all 
countries to the south of these countries were considered Southern Europe.
Within this study we did not assess the clinical relevance of these isolates. Ethical approval 
was waived for this retrospective laboratory database study.
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Results
Overview
Sixty-two centres from 30 countries across six continents participated in this study. 17 
national reference laboratories provided data representative for their whole country. For 
other countries, data was provided by a certain number of labs not covering the whole 
country. A total of 20182 patients had NTM species cultured from pulmonary samples in 
these centers in 2008; 91.3% (n= 18418) of the isolates were identified to species/complex 
level; the remaining 1765 isolates (8.7%) were not identified beyond Mycobacterium species 
other than M. tuberculosis complex. 
A total of 91 different NTM species were encountered in this survey. The most commonly used 
identification assays were the GenoType CM/AS (n=28; Hain Lifescience, Nehren, Germany), 
AccuProbe assays (n=9; Gen-Probe, San Diego, USA), hsp65 PRA (n=6), Inno-LiPA Mycobacteria 
v2 (n=3; Innogenetics, Ghent, Belgium), in-house methods (n=6) or combinations thereof; 
mostly, these were supplemented by 16S rDNA sequencing. The six most frequently isolated 
NTM were M. avium complex (9421 isolates; 47%), M. gordonae (2170; 11%), M. xenopi 
(1605; 8%), M. fortuitum complex (1322; 7%), M. abscessus (664; 3%), and M. kansasii (720; 
4%) (Figure 1). These six species accounted for 80% of all mycobacteria identified.
Figure 1: Worldwide distribution of different nontuberculous mycobacteria from pulmonary samples 
in 2008. A: M. avium complex; B: M. kansasii; C: M. xenopi; D: M. malmoense; E: M. abscessus; 
F: M. fortuitum.
Note: the data presented in this figure are not per se representative for each country. Species 
diversity may differ per country. 
23
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples
2
Continent N u m b e r 
of labs
Number of 
patients with 
NTM isolated
Distribution of NTM Number of MAC 
isolates 
(% of all NTM)
Distribution of MAC
Europe 43 6804 2500 (36.9)
North America 4 4913 2553 (52)
South America 3 393 123 (31.3)
Australia 
(Queensland)
1 453 322 (71.1)
Asia 3 1974 1062 (53.8)
South Africa 2 5646 2849 (50.5)
TOTAL 56 20183 9409 (46.6)
Table 1: Continental distribution of respiratory nontuberculous mycobacteria (NTM) isolates. MAC: 
M. avium complex; RGM: rapid growing mycobacteria; SGM: slow growing mycobacteria.
Species isolation worldwide
In this section, the isolation of different NTM is presented. Table 1 shows pie charts for M. 
avium complex and other common NTM per continent. Figure 1 presents the distribution of 
the most common NTM on a world map.
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Mycobacterium avium complex
The M. avium complex (MAC) species accounted for 9421 (47%) of the 20182 isolates in the 
study. The highest relative contribution of MAC per continent was found in Australia (71%), 
the lowest in South America (31%). Per country, this figure differed from 79% in Japan to 16% 
in Hungary. Fifty-nine out of 62 laboratories were able to identify MAC isolates to species 
level; the relative frequency of M. intracellulare versus M. avium in different parts of the 
world is shown in Table 1. The most striking difference is the relative predominance, within 
the participating sites, of M. avium in North- and South America. 
In contrast, M. intracellulare was most frequent in Australia-Queensland (57% of all 
mycobacteria cultured; 80% of the MAC), and South Africa (40% ; 77.5%). MAC isolates 
that were not identifiable to (sub)species level were common in participating laboratories 
in Asia and Europe (21% and 15% of all MAC isolates, respectively) but relatively rare in the 
participating laboratories in North America (8%). 
Mycobacterium gordonae
M. gordonae is the second most isolated NTM worldwide in this study mainly due to a high 
isolation rate found in Europe where M. gordonae was the second most isolated NTM. On all 
other continents, M. gordonae ranked third (North America, South America, Africa), or fourth 
(Asia, Australia).  
Mycobacterium xenopi
After MAC and M. gordonae, M. xenopi was the third most frequently isolated species in the 
survey, though its isolation was limited to distinct geographical regions, mainly in Europe 
and Ontario, eastern Canada (but not Alberta, western Canada). In Hungary, M. xenopi is the 
predominant NTM isolate comprising 49% of all the NTM in this country. In Croatia M. xenopi 
was the second most frequent isolated NTM after M. gordonae. Furthermore, M. xenopi 
was prevalent in the English Channel region, being the second most frequent NTM isolate in 
Belgium and south-east England and ranked third in France after MAC and M. gordonae. 
Differences within countries were also observed: M. xenopi was the predominant NTM 
isolate in the Barcelona area but only ranked third after MAC and M. fortuitum in the Madrid 
area. M. xenopi was not isolated in the participating centers from Asia, Australia and South 
America.
Mycobacterium kansasii
Overall, M. kansasii was the sixth most frequently isolated NTM. In South America M. kansasii 
was the second most isolated NTM after MAC accounting for 19.8% of all NTM isolated. 
In Europe, Slovakia, Poland, and the UK had the highest M. kansasii isolation rates of 36%, 
35%,  and 11% respectively, compared to a mean isolation of 5% in Europe. In the Paris 
region of France, M. kansasii was the third most isolated NTM after MAC. In the participating 
laboratory in Japan, M. kansasii ranked fourth after MAC, M. gordonae and M. abscessus. In 
South Africa, M. kansasii ranked sixth overall. In a center with a large miners community in 
the Johannesburg region however, M. kansasii was the second most frequent NTM isolated.
Rapid growers
M. abscessus and M. fortuitum were the most frequently isolated rapidly growing mycobacteria 
(RGM) worldwide. Other RGM were only sporadically isolated.
Among the RGM, important geographical differences were observed. RGM were highly 
prevalent isolates in the participating centers in East Asia, where they make up 27% of 
all NTM isolates in comparison to isolation frequencies of 17.9%, 16%, and 14% in the 
participating centers in North America, South America and Europe, respectively. However, 
important differences in frequency of RGM isolation among countries within Asia were also 
noted. In Tokyo, Japan, rapid growers accounted for only 6.6% of all isolates, in contrast to 
the participating centers in Taiwan (50%) and South Korea (28.7%). Furthermore, in Taiwan, 
M. fortuitum and M. abscessus were the second and third most frequently isolated NTM 
species, while in South Korea, M. abscessus was the second most frequently isolated NTM 
after MAC. 
Rare and geographically restricted NTM species
M. malmoense was found more often in Northern Europe (total of 80 of 3107 isolates; 
2.6%) in comparison with Southern Europe (21 of 3696 isolates; 0.6%). In South Africa, 43 
M. malmoense isolates were found (43 of 5646; 0.76%). Five M. malmoense isolates from 
the participating laboratories from North America were reported (5 of 4913 isolates; 0.1%). 
M. malmoense was not found in Queensland-Australia, Asia, and South America. M. simiae 
was found worldwide except Asia. A total of 97 patients were found in this study with an 
M. simiae isolate (0.5% of all 20182 NTM isolated). M. scrofulaceum was the second most 
isolated NTM in South Africa (383 isolates of 5646; 6.8%). M. lentiflavum was found in several 
labs worldwide (generally below 1% of all NTM isolated per lab) but was found more often 
in Portugal (6%) and Finland (5.8%). The majority of the 91 different NTM species in this 
study were infrequently isolated, e.g. M. smegmatis (n=5; 0.03%) and M. interjectum (n=36; 
0.2%).
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Focus on Europe
Because of a substantial number of participating countries in Europe, this continent was 
studied in more detail, with a focus on north-south differences. We collected data of 3107 
isolates from Northern Europe and 3696 from Southern Europe. In Figure 2, the pie-charts of 
species diversity in all participating countries in Europe are shown. 
MAC was isolated more frequently in Northern Europe (44% of all mycobacteria) than in 
Southern Europe (31%). In both north and south Europe, M. avium was the most frequent 
isolated subspecies of the MAC. 
M. xenopi was more frequently isolated in Southern (778 of 3697 isolates; 21%) compared to 
Northern Europe (190 of 3107 isolates; 6%) partly due to substantial contribution of M. xenopi 
isolated in a single country (Hungary). On the other hand, M. bohemicum was especially 
found in Northern Europe, mainly Finland, in contrast to only 1 isolate from Southern Europe 
and no isolate from any participating laboratory in other regions of the world. 
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Figure 2: Distribution of different nontuberculous mycobacteria from pulmonary samples in 2008 
in Europe. MAC: M. avium complex; RGM: rapid growing mycobacteria; SGM: slow growing 
mycobacteria.
Discussion
For the first time, we provide a snapshot of the worldwide distribution of NTM species isolated 
from pulmonary samples. This snapshot illustrates that the species distribution among NTM 
isolated from pulmonary specimens in the year 2008 differs by region and differs by country 
within these regions. For many regions or countries that participated in this study, these are 
the first data covering this topic. The NTM species distribution in a country or region may 
have profound impact on the frequencies and manifestations of pulmonary NTM disease. 
It is now generally accepted that NTM species differ in their ability to cause lung disease in 
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humans3-6 and that the clinical relevance of a particular species can differ in different parts 
of the world.7, 8 The species distribution presented in this study can help in identifying factors 
associated with human NTM infection like climate differences, population density, or host 
factors. In the past, it has been suggested that differences in NTM species distribution may 
also affect the efficacy of BCG vaccination.9 
The two studies that approached this subject were published by Martin-Casabona and 
colleagues in 20042 and by Marras and Daley in 2002;3 the former reported on NTM isolation 
over three decades, ending in 1996. The spread of molecular tools for identification in 
the years between 1996 and 2008 make the comparison of the two surveys difficult. The 
Martin-Casabona study only incorporated laboratories from Europe, Turkey, Iran and Brazil 
and sampling was not systematic as different laboratories produced data from different time 
periods. The review by Marras and Daley adds more historical published data and is not a 
survey. Still, both showed the predominance of MAC isolation worldwide together with the 
characteristic geographical distribution of M. xenopi, M. kansasii, and M. malmoense. The 
review by Marras and Daley also showed that differences in species distribution may occur 
over time.3
In this study, the members of the M. avium complex predominated in most regions, though 
M. xenopi predominated in Hungary and M. kansasii in Poland and Slovakia. The relative 
distribution of the various members of MAC again reveals geographic differences. While M. 
avium predominated in the participating centers in North and South America and Europe, 
M. intracellulare was most frequently isolated in South Africa and Australia. In Australia a 
significant increase in the isolation of this species has been reported before5. Few laboratories 
were able to reliably distinguish the novel MAC members, such as M. colombiense and M. 
chimaera.10, 11
Mycobacterium xenopi was particularly prevalent in the region covering Hungary, Croatia, 
Northern Italy, in Ontario-Canada and in the areas bordering the English Channel; the latter 
two are in line with earlier data.1, 2 The frequently stated link to coastal areas1, 2 does not hold 
true in the light of the observed predominance in Hungary and absence in coastal regions 
outside Europe. Nonetheless, presence of a specific environmental niche for M. xenopi is a 
likely explanation. Other factors to be considered are differences in the potential to colonize 
or infect human airways between M. xenopi strains and host factors.
The geographical distribution of M. kansasii has been the subject of previous studies. In our 
study, M. kansasii was frequently isolated in South America, Eastern Europe and metropolitan 
centers Paris, London and Tokyo and the Johannesburg region of South Africa. These findings 
match previously published data from those regions.2, 8 Its isolation has been related to mining 
activities12-14 as well as urbanization and may be related to working and living conditions.15 
In Northern Europe, isolation frequencies of M. kansasii have been in decline for the past 
three decades,16 but the underlying causes are unknown. The high isolation frequency of 
M. scrofulaceum in South Africa is in accordance with the literature and probably related to 
mining activities.14
M. simiae was traditionally thought to be confined to the Southern USA, Cuba and Israel,7 but 
in this study we demonstrate that this species has a global distribution (except Asia), making 
up 0.67% of all isolates in this study, with the highest isolation of 1.1% found in northern 
Europe. M. malmoense was found especially in Northern Europe, which is in accordance with 
the literature,8 but also in South Africa. M. malmoense isolation from clinical specimens from 
this continent has never been reported before, although its presence in soil was.17
Rapid growers made up 10-20% of all NTM isolates worldwide, although they proved more 
prevalent in East Asia where they compose up to 50% (Taiwan) of all NTM isolated from 
pulmonary samples. The high isolation frequency of RGM, particularly M. abscessus, was 
also noted in previous studies, focusing on this region.18-20 The reason for the high isolation 
rate of RGM in Asian countries remains unclear, though geographical or climatic factors, 
host and laboratory factors have been suggested.19 An important reason to perform studies 
on geographical distribution of NTM is to help identify factors associated with differences 
in worldwide isolation patterns of specific species. Studies focusing on species-specific 
environmental niches and subsequent transmission to humans are not systematically 
performed. Yet, these can offer important clues that aid to prevent (re)infection of susceptible 
patients. 
In the current study, a multitude of molecular identification techniques was used. It is 
well known that these techniques can produce discrepant results.21, 22 Yet, this is likely to 
influence a minority of isolates and will not affect the snapshot of the geographic diversity 
in NTM species isolated from pulmonary samples, as presented in this study. The current 
study revealed the occasional presence of many rare species. For many of these species no 
data other than reports of single cases of disease were available. Often such case reports or 
novel species descriptions seem to suggest a very limited geographic spread of the bacterium 
and, as they mostly concern cases of true disease, overestimate the clinical relevance of 
these rare species. We hope that the current study also provides a reference to clinicians and 
microbiologists faced with rare NTM species.
An important shortcoming of this study is the low number of participating laboratories, 
especially outside Europe. Inclusion of more data from different laboratories will probably 
reveal other isolation patterns. 
Follow-up studies covering different time periods together with more participating laboratories 
may reveal additional clues on changing NTM pattern over time and geographic differences 
of NTM distribution on the national scale. 
We have chosen pulmonary samples specifically because these best reflect the distribution 
of species in local environments. Nevertheless, the presence and persistence within the 
human airways is also likely to represent a selection bias, as does the fact that we collected 
identification results of cultured isolates. The low isolation frequency of the majority of 
the 91 different NTM species may reflect an inability to persist in human airways or scarce 
environmental presence. 
In summary, this snapshot illustrates that the species distribution among NTM isolated from 
pulmonary specimens in the year 2008 differs by region and differs by country within these 
regions. MAC predominates in most settings, but the frequency of isolation of rapid growers, 
or slow growers like M. xenopi, M. kansasii and M. malmoense differs per setting. These 
differences in species distribution may determine, in part, the frequency and manifestations 
of pulmonary NTM disease in each region. Future studies need to address species-specific 
environmental niches as a cause of differences in worldwide isolation patterns.
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Abstract
Setting: National mycobacteria reference laboratory, the Netherlands.
Objective: To assess the role of factors other than laboratory improvements in the increasing 
isolation frequency of nontuberculous mycobacteria (NTM) in the Netherlands; laboratory 
improvements are often considered key factors in this increase.
Design: Laboratory database study. All clinically isolated NTM referred to the national 
reference laboratory between January 2000 and January 2007 were retrieved from the 
laboratory database and divided by species, patient age group and sample origin. Data were 
compared to national demographic data.
Results: Clinical Mycobacterium avium isolates accounted for most of the increase in 
referred NTM. The number of respiratory M. avium samples in patients >40 years of age 
increased over time. This age group increased in size during the study. In this age group, 
the prevalence of chronic obstructive pulmonary disease (COPD) increased during the study 
period. Mycobacterium avium isolation from lymph nodes in children remained stable, 
whereas extrapulmonary M. avium isolation in the middle age group, including HIV-associated 
bloodstream isolates, decreased. 
Conclusions: The increasing NTM notification in the Netherlands is unlikely to have been a 
result of laboratory improvements alone: the ageing population with an increasing prevalence 
of COPD is likely as important. Environmental characteristics may specifically favour M. 
avium.
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Introduction
Nontuberculous mycobacteria (NTM) are mostly opportunistic pathogens that are widely 
present in natural and man-made environments.1 The frequency of isolation of NTM is 
increasing in many countries, mainly were the incidence of tuberculosis (TB) is in decline.1-3 
This increase in isolation frequency has previously been related to laboratory improvements 
for detection and identification of NTM, including automated liquid culture systems and 
molecular identification kits.1-2 The pathogenic potential of these NTM, however, is increasingly 
recognized, especially in patients at risk due to local or systemic impaired immunity.1 
At the Dutch national mycobacteria reference laboratory at the National Institute for Public 
Health and the Environment (RIVM), we also noted an increase in the number of referred 
NTM, most notably isolates belonging to the Mycobacterium avium complex (MAC). 
In the present study, we explored the factors underlying this increase in NTM isolation.
Methods
Records of all clinical isolates of nontuberculous mycobacteria referred in between January 
2000 and January 2007 were extracted from the reference laboratory database and divided 
by species, sample origin (respiratory, lymph node or other) and age group; one isolate per 
patient per year was analyzed, unless multiple species were identified. Age was defined 
as the age at the date of primary sampling. We chose the following categories: 1-12 years 
old to include mostly the children with lymphadenitis; 13-39 years to include mostly 
immunocompromised patients, including co-infection with the human immunodeficiency 
virus (HIV) and cystic fibrosis patients; >40 years to include mostly patients with pre-existent 
pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD)4. The latter group 
was subdivided in the 40-60 and >60 years. We compared the laboratory data with publicly 
available demographic data of the Dutch Central Bureau for Statistics (CBS; http://www.cbs.
nl); data on population size, age distribution and COPD prevalence were extracted.
The isolates of all patients were subjected to laboratory diagnosis by the RIVM, the national 
reference laboratory that performs identification, drug susceptibility testing and genotyping of 
Mycobacterium isolates for all hospitals in the Netherlands. An estimated 85% of all clinically 
isolated NTM is referred here. To identify mycobacteria, a GenoType MTBC reverse line probe 
assay (Hain Lifesciences, Nehren, Germany) is used after polymerase chain reaction based 
amplification to determine whether an isolate is a member of the M. tuberculosis complex. 
If the reaction is negative, an Inno-LiPA Mycobacteria v2 (Innogenetics, Gent, Belgium) 
reverse line blot assay is used to differentiate between the more common species of NTM. 
If no species-specific result is obtained, 16S rDNA gene sequencing is performed. Prior to 
2004, 16S rDNA gene sequence analysis was performed on request of referring physicians, if 
AccuProbe M. tuberculosis complex, M. avium complex, M. intracellulare and M. avium DNA 
probes (GenProbe, San Diego, USA) yielded negative results. 
Ethical approval was waived for this retrospective study.
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Results
During the study period, the annual number of referred NTM rose in absolute terms from 480 
to 747 per year, as well as relative to M. tuberculosis isolation (Table 1). Isolates belonging to 
the MAC, made up of M. avium and M. intracellulare, are the NTM most commonly isolated 
in the Netherlands, and their number rose sharply during the study period from 170 to 292 
per year, comprising respectively 35% to 39% of annually referred NTM (Table 1). 
During our study period, the increase in referred MAC isolates was caused mainly by an 
increase in M. avium isolates (Table 1) from 60 in 2000 to 210 in 2006, a 250% increase. This 
increasing annual trend, as compared to the general annual NTM count, proved statistically 
significant (Pearson’s r 0.857; p=0.014). The number of M. intracellulare isolates was stable 
(Table 1). This rise in M. avium isolates has two important features. First, it is most pronounced 
in patients aged >40 years (Table 2). Second, it is mainly caused by a rise in M. avium isolates 
from pulmonary samples (Table 2). These pulmonary isolates are cultured almost exclusively 
from the patients aged >40 years (p<0.001); within these group, pulmonary isolates are 
significantly associated with age > 60 years (p<0.001). In general, the sample origin recorded 
was in agreement with the origins expected within the age group (Table 3).
During the study period, the demographic composition of the Netherlands changed. Between 
2000 and 2008, the population increased by 3.3%, although this percentage was 12.2% for 
those aged 40 to 65-years and 10.9% among those aged >65 years, and by 2008, 50.1% of 
the Dutch population was aged >40 years (Table 4). The self-reported prevalence of COPD 
increased from 7.0% in 2000 to 7.6% in 2006; in persons aged 45-65 it increased from 5.2% 
to 7.7%, while in those aged >65 years it increased from 9.6% to 12.7%.
The number of extrapulmonary samples, including those from children with cervical 
lymphadenitis, remained relatively stable throughout the study period (Table 2). 
The increase in the annual number of referred isolates is not confined to M. avium, although 
for this species it is most pronounced. M. gordonae isolates are also increasing in number, 
whereas isolation of other important species including M. intracellulare, M. malmoense and 
M. kansasii has been mostly stable (Table 1).
Year 2000 
n (%)
2001 
n (%)
2002 
n (%)
2003 
n (%)
2004 
n (%)
2005 
n (%)
2006 
n (%)
Total mycobacteria 1584 1604 1536 1480 1567 1561 1537
M. tuberculosis complex 1104 1111 1098 1009 933 893 790
Total NTM 480 493 438 471 634 668 747
MAC 170 175 161 191 267 278 292 
-M. avium 60 61 56 81 191 215 210 
-M. intracellulare 26 33 18 26 59 58 54
-Untyped MAC 84 81 93 84 17 5 28
M. malmoense 17 10 18 6 16 20 17
M. gordonae 57 45 40 49 112 99 152
M. marinum 5 8 7 7 13 12 20
M. kansasii 39 39 32 34 53 45 50
Table 1: Annual laboratory data for the study period*
*Percentages are fractions of “Total NTM”. The increase in the isolation frequency of M. avium is not mirrored in other NTM species, 
including M. kansasii, M. malmoense and M. marinum. Many NTM species were referred in low numbers and not included in the Table to 
increase clarity. NTM, nontuberculous mycobacteria; MAC, Mycobacterium avium complex;
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2000 2001 2002 2003 2004 2005 2006
Total 60 61 56 81 191 215 210
Pulmonary 38 42 42 59 125 155 156
Lymph node 12 7 4 12 42 39 32
Other 10 12 10 10 24 21 22
Age Group, years*
1-12 11 10 5 11 43 40 26
13-39 8 9 9 9 33 24 18
40-60 18 12 14 27 32 47 53
>60 23 30 28 34 83 104 113
Table 2: Isolation sources and age distribution of Mycobacterium avium isolates by year
*The increase in M. avium isolation mainly results from pulmonary isolates and patients aged >40 years.
Age group Lymph node Other Pulmonary Total
0-12 159 16 10 185
13-39 7 70 112 189
40-60 10 52 326 388
>60 6 24 748 778
Total 182 162 1196 1540
Table 3: The number of MAC isolates by sample origin and age group*
*Pulmonary isolates are significantly associated with patients >40 years of age (p<0.001); within this group,
    they are significantly associated with patients >60 years old (p<0.001)
Year 2000 2008 Increase %
Population size 15863950 16405399 541449 3.3%
Age group, years*
0-20 3873008 3940450 67442 1.7%
20-40 4761504 4267063 -494441 -10.4%
40-65 5076996 5783060 706064 12.2%
65-80 1652103 1799337 147234 8.2%
>65 2152442 2414826 262384 10.9%
>80 500339 615489 115150 18.7%
Table 4: Demographic data for the Netherlands, 2000-2008
*The Dutch population is ageing; growth of the population is concentrated in the segment >40 years old.
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Discussion
The rise in isolation frequency of NTM in the Netherlands is caused mostly by increasing 
numbers of M. avium isolates from respiratory samples in patients aged >40 years. These are 
probably patients suffering from COPD, the most common predisposing condition for NTM 
lung disease within this age group in the Netherlands and an argument for frequent culture 
of sputum samples.5 A recent study in the Netherlands demonstrated that M. avium was 
more common than M. intracellulare in pulmonary samples. Moreover, pulmonary M. avium 
isolation represented true disease in 24 of 59 cases (41%) as opposed to 2/16 cases (13%) for 
M. intracellulare, based on the 2007 ATS criteria.1,5 
Importantly, this study also demonstrated that among pulmonary MAC isolates, the percentage 
representing true MAC disease did not change significantly in the 1999-2004 period;5 this 
suggests that the increase in isolation frequency is not a mere result of an increased sample 
volume. Moreover, clinical guidelines for COPD or other pulmonary diseases predisposing 
to NTM disease have not changed with respect to Mycobacterium culture during the study 
period. Reports from the USA have noted that the nodular-bronchiectatic type of pulmonary 
MAC disease is most frequent there and M. intracellulare its most common causative agent.6 
These differences remain largely unexplained. It is possible that M. avium bacteria isolated 
in the Netherlands differ in virulence from those isolated in the USA; previous studies have 
identified genetic differences in MAC isolates from different human and environmental 
sources.7-8 
The improvements in culture and identification techniques often held responsible for rising 
NTM isolation frequencies1-2 are also relevant in the Netherlands. Automated liquid culture 
systems were introduced in September 1997; their spread largely predates our study. 
Improvements in the identification methods at our reference lab in 2004 (see Methods) 
led to a decrease in the number of untyped MAC strains and an increase in the number of 
isolates identified as M. intracellulare or M. avium (Table 1). It is evident from Table 1 that 
this provides only a partial explanation of the increase in M. avium isolates in 2004. Tables 1 
and 2 show that, although boosted by improved identification methods, the increase in M. 
avium isolation, especially among the oldest age groups, began before the improvements in 
laboratory techniques. Moreover, the annual number of isolates of other species, including 
the commonly isolated M. kansasii, M. intracellulare and M. malmoense did not benefit from 
these technical improvements (Table 1), nor did the number of extrapulmonary M. avium 
isolates (Table 2) or the percentage of TB cases that could not be confirmed by culture; this 
has been steady in the Netherlands throughout the study period, at 30%.9 Skin sensitization 
to M. intracellulare has increased over the last decades in the US, along with the incidence of 
M. intracellulare infection.10 Combined, this suggests that laboratory techniques have a role 
in the increase in NTM, thus M. avium isolation, but are not its sole explanation. 
Host factors provide a second partial explanation for the rise in NTM isolation frequency. 
The Dutch population is ageing (Table 4) and reports an increasing prevalence of chronic 
respiratory disease, an important risk factor for NTM disease.5 The increasing prevalence of 
COPD was also noted in a recent study of morbidity and interventions in general practice.11 
The prevalence of COPD may partially explain the increase in NTM notification in pulmonary 
samples (Tables 2 and 3). Patients in older age groups are more likely to have chronic pulmonary 
diseases accompanied by sputum production than younger patients. However, this offers 
no explanation for the rise in isolation specifically of M. avium unless COPD predisposes to 
infection by M. avium rather than other NTM species. In the Netherlands, the fibrocavitary 
disease type is more prevalent, primarily affects COPD patients and is mostly caused by M. 
avium.5 It is uncertain whether the predominance of cavitary MAC disease results from the 
strong presence of M. avium as opposed to M. intracellulare, or from host factors including 
COPD. Rather than rising COPD prevalence, the simultaneous decline in tuberculosis incidence 
(Table 1) may imply that exposure to tuberculosis infers cross-protection to NTM disease; this 
is supported by the fact that countries that halted bacille Calmette-Guerin (BCG) vaccination 
subsequently noticed an increase in the incidence of paediatric cervicofacial lymphadenitis 
caused by MAC.12-13
A third explanation for the increase in M. avium isolation in the Netherlands may be changes in 
the environment, either natural or man-made, that favour M. avium and impede or influence 
other NTM; these could result in increased exposure of humans specifically to M. avium. 
Similarly, in the 1970’s M. scrofulaceum was replaced by MAC as the leading causative agent 
of cervical lymphadenitis in children. This phenomenon has been attributed to chlorination 
of tap water, which likely selects for the more chlorine resistant M. avium.14 Studies reviewed 
by Collins et al., however, did not demonstrate important differences in chlorine susceptibility 
between NTM species and considered tap water chlorine levels too low to significantly reduce 
mycobacterial loads.15
The number of M. avium isolates from lymph node samples referred to our reference 
laboratory has remained relatively stable; the temporary elevation in 2004-2005 results from 
a clinical trial in that period.16 The stable low numbers of other extrapulmonary M. avium 
isolates probably result, in part, from the availability of highly active antiretroviral therapy 
(HAART) and MAC prophylaxis for patients infected with HIV; one of the important limitations 
of the current study is the lack of clinical data, including HIV serostatus. A decline in the 
incidence of disseminated M. avium disease during and after HAART introduction has been 
recorded and reviewed before.17 NTM infection usually affects patients with very low CD4 
counts and their numbers have been reduced after the introduction of HAART.
In summary, the rise in notification of nontuberculous mycobacteria at the reference laboratory 
in the Netherlands was mainly caused by increasing isolation of M. avium from respiratory 
samples in patients aged  >40 years. Changes in laboratory techniques are unlikely to be the 
sole explanation of this increase. The ageing population, with an increasing prevalence of 
chronic diseases including COPD, is likely as important. Decreasing cross-protection to NTM 
disease from exposure to TB may also play a role. Environmental changes may specifically 
favour M. avium.
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Abstract
Objective: The aim of the present study was to investigate the isolation prevalence of NTM 
among patients presenting with an acute exacerbation of chronic obstructive pulmonary 
disease (AECOPD).
Design: All patients with an AECOPD who were admitted to our pulmonary hospital or seen 
at the outpatient department between January 2010 and January 2011 were included in this 
prospective cohort study. At least 3 separate sputum samples were tested for the presence 
of NTM by culture on solid and liquid media.
Results: We included 73 patients with a mean age of 70.4 ± 10,7 years, of whom 44 were male 
(60%) with a mean FEV1 of 44.2% predicted. A total of 206 sputum samples were obtained; 21 
samples (10.1%) of 16 patients (22%) yielded mycobacteria, 14 of 21 were M. gordonae. One 
patient was diagnosed with definite NTM lung disease. Patients with a positive mycobacterial 
culture were significantly older than patients without a positive mycobacterial culture.
Conclusion: In the current cohort of patients presenting with an AE COPD, 22% harbored 
NTM in their sputum. Further study is required to address the clinical importance of these 
NTM and their relation with COPD.
45
Prevalence of NTM in COPD exacerbations
4
Introduction
Nontuberculous mycobacteria (NTM) are environmental micro-organisms omnipresent in 
soil, plants and natural and treated water. More than 130 different NTM species have been 
identified and still new species are described. Humans contract NTM infections mainly from 
environmental sources (aerosols, ingestions); person-to-person transmission has not been 
proven. The frequency of NTM isolation in clinical practice is increasing in many countries, 
including the Netherlands.1-4 NTM are mostly opportunistic pathogens and capable of causing 
disease in patients with local or systemic impaired immunity. 
Pulmonary NTM disease is most frequent and generally affects patients with pre-existing 
chronic pulmonary diseases, mainly chronic obstructive pulmonary disease (COPD).1,3 COPD 
is the fourth leading cause of death in the world, and further increase in its prevalence and 
mortality can be anticipated in the coming decades. Pulmonary infections, including those by 
NTM, may contribute to the progression of COPD. There is little published information about 
the prevalence of NTM in the lung of COPD patients. Only when there are strong indications 
of a possible role of NTM in the disease progression, mycobacterial culture is requested. We 
performed a prospective cohort-study in COPD patients presenting with an exacerbation to 
determine the prevalence and clinical relevance of NTM isolation in COPD patients. 
Materials & Methods
Study design and setting
We performed a prospective cohort study. The cohort includes all patients admitted to our 
pulmonary hospital and patients seen in the outpatient department between January 2010 
and January 2011with an acute exacerbation of COPD (AECOPD). AECOPD was chosen as 
an inclusion parameter because of the potential ease of sputum collection in exacerbated 
patients. A COPD diagnosis made by spirometry was required before inclusion in the study. 
An AECOPD diagnosis was established by the responsible physician. AECOPD was defined, 
according to the Global Initiative for Chronic obstructive Lung Disease (www.goldcopd.com) 
as an event in the natural course of the disease characterized by a change in the patient's 
baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is acute 
in onset, and may warrant a change in regular medication. We excluded patients referred to 
our clinic for previously diagnosed pulmonary NTM disease. Written informed consent was 
obtained from all patients. The study was approved by the local ethics committee.
Study procedures
The main outcome in this study was the result of mycobacterial sputum culture. As part of 
routine clinical practice in our center, sputum samples and chest radiographs were obtained. 
We aimed to obtain three sputum samples per patient on separate days for mycobacterial 
culture. If one of these samples grew positive for mycobacteria, two successive samples were 
obtained on separate days in order to determine whether the American Thoracic Society 
(ATS) microbiological criteria for NTM disease were met. In the ATS statement, true NTM 
lung disease is defined by at least two positive sputum cultures in combination with fitting 
clinical parameters (pulmonary symptoms and radiologic abnormalities associated with 
NTM disease).1 Patients treated in the outpatient department were asked to mail successive 
sputum samples to the hospital. A systematical description of chest radiographs was not part 
of the study protocol. Patients were asked to complete a short written questionnaire about 
symptoms, and possible factors associated with NTM presence (smoking history, (inhaled) 
corticosteroid use, previous exacerbations, and hospital admissions). Level of dyspnoea was 
measured using the mMRC dyspnoea scale as part of routine clinical practice in our hospital.5 
No systematic follow-up was planned for this study.
Mycobacteriological examination
Concentrated sputum samples were decontaminated for 10 minutes using 1% N-acetyl-L-
cysteine-sodium hydroxide and incubated on solid egg-based media (Lowenstein-Jensen, BD 
Biosciences, Erembodegem, Belgium) at 30 and 35°C as well as in liquid medium (BacTec 
MGIT960, BD Biosciences, Erembodegem, Belgium) at 35°C. We subjected all isolates to Ziehl-
Neelsen staining and positives were subjected to molecular identification using the INNO-
LiPA Mycobacteria v2 reverse line blot assay (Innogenetics, Ghent, Belgium); if a non-specific 
result was obtained, the hypervariable region A of the 16S rRNA gene was sequenced.6
Statistical analysis
Data are described as mean + standard deviation or median (quartile). Comparisons between 
groups were done with Student t test for normally distributed variables and with Mann-
Whitney Rank Sum Test for those with non normal distribution. Chi-square and Fisher exact 
tests were used for categorical variables.
Results
Inclusion
Eighty-one patients were eligible for inclusion, of whom 73 were ultimately included during 
the study period. Eight patients were excluded. The reasons for exclusion were: pulmonary 
function tests showed no airflow obstruction (n=3) or pulmonary function tests not available 
(n=2), no informed consent given (n=1) or no sputum cultures available (n=2).  The mean age 
of the 73 patients was 70.4 ± 10.7 years, of whom 44 were male (60%) with a mean FEV1 of 
44.2% predicted. Sixty-four patients (88%) were admitted to the hospital at time of inclusion. 
Twenty-one patients (29%) showed dense airspace opacities on chest X-ray at inclusion. None 
of the patients were treated with a macrolide before inclusion.
Sputum cultures
A total of 206 sputum samples were collected during the study period (206/73=2.82 
sputum samples/patient (SD ± 0.78)). Of these 206 sputum samples, 21 were positive 
46
Chapter 4
for mycobacteria (10.1%; 14 M. gordonae, 1 M. avium, 3 M. chimaera, 2 M. simiae, 1 M. 
nonchromogenicum). The total number of patients from whom a mycobacterium was 
cultured was 16 (22.2%); 11 M. gordonae, 1 M. avium, 2 M. chimaera, 1 M. simiae, 1 M. 
gordonae and M. nonchromogenicum). Four patients (25% of all the patients with a positive 
NTM culture and 5.4% of all the included patients) had two positive cultures yielding the 
same NTM species (M. simiae [n=1], M. chimaera [n=1] and M. gordonae [n=2]) (Table 1). 
The patient with M. simiae isolated was diagnosed with definite NTM lung disease. The patient 
with two M. chimaera isolates showed dense airspace opacities on radiologic examination 
that recovered with standard antibiotics. He was known with fibrotic abnormalities of both 
upper lobes including bronchiectasis that were not changed on chest radiograph. Clinical 
data of the patients with one positive NTM culture (n=11) or two NTM cultures of different 
species (n=1) is presented in Table 2. 
One patient, diagnosed with bronchiectasis, had 2 different mycobacteria cultured (M. 
gordonae and M. nonchromogenicum). Of the patients with a positive mycobacterial culture, 
six were previously diagnosed with bronchiectasis, in five patients bronchiectasis were 
excluded by a recent HRCT and in four patients the presence of bronchiectasis was unknown. 
Only the patient with M. simiae isolates had a Ziehl-Neelsen stain positive sputum smear. 
The 16 patients with a positive mycobacterial culture were significantly older than patients 
without a positive mycobacterial culture (76.3 ± 8.4 years vs. 68.51 ± 10.7 respectively; 
p=0.009) (Table 3). When the patients with one positive M. gordonae culture (n=9, 12.3% 
of all the included patients) were excluded, the patients with positive mycobacterial isolates 
were still significantly older than patients without mycobacterial isolates (76,9 ± 7,6 years 
vs. 69.5 ± 10.5 respectively; p=0.009). Patients with a NTM isolated were all non-smokers at 
inclusion. Other patient characteristics were not associated with NTM isolation (Table 3).
Non-mycobacterial pathogens were cultured in 45 patients (62%). Haemophilus influenzae 
was the most frequently seen pathogen (cultured in 14 patients, 19.2%), followed by 
Pseudomonas aeruginosa (cultured in 12 patients, 16.4%), and Streptococcus pneumoniae 
(cultured in 5 patients, 6.8%). Positive sputum culture with non-NTM species was not 
associated with having a positive NTM culture (p=0.508).
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Patient Sex/
Age
NTM species Other 
pathogens
FEV1 
(%pred)
Radiology ATS 
criteria 
met?
Treatment Routine 
follow-up
A M/78 M. simiae S. aureus, 
later: E. 
cloacae
81 HRCT: Emphysema 
and bronchiectasis. 
Nodular pattern left 
lower lobe.
Yes R/E/Cla 1 
year
Sputum 
conversion
B M/81 M. chimaera S. 
pneumonia
42 Radiograph: dense 
airspace opacities 
right lower lobe.
Fibrotic lesions 
and bronchiectasis 
both upper lobes, 
unchanged.
No None M. 
intracellulare 
(1 x)
C M/80 M. gordonae: 
sputum and 
BAL (8 weeks 
in between)
37 HRCT: 
bronchiectasis 
lower lobes
No Co-
trimoxazol 
for 
suspected 
pulmonary 
nocardiosis
No 
mycobacteria 
cultured
D F/66 M. gordonae 
(isolated on 
same day)
None 85 Radiograph: 
Consolidation 
right upper lobe. 
Emphysema.
No None No 
mycobacteria 
cultured
Tabel 1: Clinical aspects and treatment of the patients with two mycobacteria cultured of the 
 same species.
ATS: American Thoracic Society; Cla: clarithromycin; E: ethambutol; E. cloacae: Enterobacter cloacae; FEV1: forced 
expiratory volume in 1s; HRCT: high resolution computed tomography; NTM: nontuberculous mycobacterium; %pred: 
% predicted; S. aureus: Staphylococcus aureus; S. pneumonia: streptococcus pneumonia; R: rifampicin.
Patient Sex/Age NTM species Other pathogens FEV1 (%pred) Bronchiectasis
E F/75 M. gordonae H. influenzae 55 Unknown
F M/82 M. gordonae None 31 Unknown
G M/89 M. gordonaeM. nonchromogenicum P. aeruginosa 53 Unknown
H F/70 M. gordonae H. influenzae 44 No
I F/60 M. gordonae H. influenzae 49 No
J F/65 M. gordonae Serratia species 36 Yes
K F/73 M. chimaera None 39 Yes
L F/81 M. gordonae H. influenzae 61 No
M M/88 M. gordonae H. influenzae 28 No
N M/85 M. gordonae HSB 59 Unknown
O F/71 M. avium None 41 Yes
P M/88 M. gordonae None 70 Unknown
Tabel 2: Clinical aspects of the patients with one positive mycobacterial culture.
F: female; FEV1: forced expiratory volume in 1s; H. influenza: Haemophilus influenza; HSB: Haemolytic streptococcus 
group B; M: male; NTM: nontuberculous mycobacterium;; P. aeruginosa: Pseudomonas aeruginosa; %pred: % 
predicted.
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No NTM (n=57) NTM (n=16) p-value
Age 68,51 (10,7) 76,3 (8,3) 0.009
Male 35 (61,4%) 8 (50%) 0.41
Post-bronchodilatation
FEV1 %predicted
FVC % predicted
FEV1/FVC ratio
43,1
82,5
0.40
48,1
82,4
0,44
0.31
0.99
0.3
Mean number of admissions in 
previous year
1,4 0,75 0.097
MRC dyspnea score at t=0 2.98 (1,06) 3,2 (0,86) 0.47
ICS use
Beclomethason equivalent (mcg/
day)
43/57=75.4%
1418 (200-4000)
13/16=81.2%
1346 (200-4000)
0.97
0.8
Oral steroid use
Mean dosage (mg/day)
12/57=21.0%
6.8 (5-10)
4/16=25.0%
10 (5-15)
0.74
0.08
Smoking status
   Never
   Ex
   Current
   Unknown
1 (1,8%)
40 (71,4%)
13 (18,1%)
1 (1,8%)
2 (12,5%)
14 (87,5%)
0
2 (12,5%)
*
0.19
*
*
Alcohol consumption
    Yes
    No
    Unknown
19 (34,5%)
32 (58,2%)
4
2 (12,5%)
14 (87,5%)
0
p=0.089
Table 3: Characteristics of patients with and without a nontuberculous mycobacteria cultured during      
  the study period.
*: p-value not calculated because of low number of patients for that variable; FEV1: forced expiratory volume in 1s; 
FVC: force vital capacity; ICS: inhaled corticosteroid use; MRC: Medical Research Council; NTM: nontuberculous 
mycobacterium; OS: oral steroids.
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Discussion
Among all the 73 patients with an acute exacerbation of COPD (AECOPD) included in this study, 
22% of the patients had a positive mycobacterial culture. Such high isolation prevalence have 
not previously been reported in COPD patients. Ko et al.7 performed a prospective 1-year 
study among AECOPD patients in Hong Kong, in which 1.8% of all the mycobacterial cultures 
were positive; 0.4% yielded Mycobacterium tuberculosis and 1.4% NTM. In the study by Ko 
et al. only solid media were used for mycobacterial culture which probably (partly) explains 
the higher NTM isolation in our study since we used both solid and liquid media. Other 
prospective studies concerning solely AECOPD patients have not included mycobacterial 
cultures in their analysis. A large retrospective analysis performed in the Netherlands showed 
that of all positive pulmonary mycobacterial cultures, 49% were from COPD patients, 22% of 
these COPD patients were found to have clinically relevant NTM disease.3 
COPD seems to be a risk factor for pulmonary NTM presence and even NTM disease. In a study 
among asthma patients, those with NTM disease had a significantly worse FEV1 compared to 
asthmatic patients without NTM isolated.8 This finding probably reflects chronic obstruction 
to be a risk factor for NTM presence or disease. Bronchiectasis is a known risk factor for 
NTM disease and can be found in up to 50% of patients with moderate to severe COPD.9, 10 
A prospective study among 98 patients with bronchiectasis, NTM isolation prevalence was 
found to be 10.2%.11 Although no COPD diagnosis was reported for these patients, the mean 
FEV1- and FVC-predicted in this patient group were 63.5% and 85.8% respectively suggesting 
that a substantial number of COPD patients were enrolled. Severe airflow obstruction, one 
or more hospital admissions in the previous year, and a positive sputum culture are known 
factors associated with bronchiectasis in COPD patients.9  Since these factors were commonly 
found among our study population, bronchiectasis may have played a central role in our 
observed NTM prevalence. A more definite association cannot be extracted from our data 
since high resolution computed tomography for bronchiectasis diagnosis was not part of the 
study protocol. In our study, one patient met the ATS diagnostic criteria for NTM lung disease 
(1.4%); this patient was previously diagnosed with bronchiectasis. In another patient with 
known bronchiectasis, two M. chimaera isolates were found but the clinical condition and 
dense airspace opacities improved on a short course of doxycycline. None of the patients 
with one positive NTM culture showed clinical abnormalities associated with possible NTM 
disease; this is in line with the landmark study by Tsukamura12 and supports the microbiologic 
criteria of the ATS diagnostic criteria.1
Patients with a positive mycobacterial culture in our study were significant older than patients 
without a positive NTM culture. While no differences in airflow obstruction or corticosteroids 
use was seen between these groups, ageing may be associated with NTM presence in 
COPD patients. In the study by Fritscher et al.8 asthmatic patients with NTM disease were 
also significantly older than asthmatic patients without NTM isolates or disease. Other risk 
factors to be considered are systemic and inhaled steroid use, a factor which was found to be 
associated with NTM disease in COPD13 and asthmatic patients.8 In the study by Andréjak13 
inhaled steroid use showed a dose dependent risk for NTM disease in their case-control 
study. Steroid use was not significantly different between patients with and without NTM 
isolation in our study but still, the high isolation rate of NTM in our study among patients 
with an AECOPD may be associated with the frequent use of inhaled steroids found in 78% of 
patients in our study group. The exact role of NTM in the disease process of COPD as well as 
the mechanisms by which COPD predisposes to NTM lung disease warrant additional study.
M. gordonae contributed importantly to the observed high NTM prevalence (14/21 = 66.7%). 
M. gordonae is one of the most frequently isolated mycobacteria in the Netherlands,14 and 
in general, pulmonary M. gordonae isolates in immunocompetent patients are considered 
clinically insignificant.1 There was no clustering in time among the M. gordonae isolates which 
makes laboratory cross-contamination unlikely. In previous studies, M. gordonae isolates have 
been obtained from hospital tap water, and from sputum samples of patients collected after a 
tap water mouth rinse.15-16 However, 11 of 95 patients in the retrospective analysis of Arnow 
et al. had multiple M. gordonae positive cultures and were classified as having M. gordonae 
colonization.15 Still, the local immune suppression in COPD patients may lead to M. gordonae 
infection and disease and this needs to be actively ruled out.
Our data are not definite applicable to other settings since our study is a single center study. 
NTM are environmental mycobacteria and exposure to NTM and therefore NTM presence or 
disease in humans can differ per environmental setting. Multi-center studies are therefore 
needed to confirm our results.
In conclusion, NTM were isolated from 22% of the patients presenting with an AECOPD. 
NTM isolation was more frequent in elderly patients. No other factors were shown to be 
associated with NTM isolation in our study although bronchiectasis and steroid use can be 
important predisposing factors. The most frequently isolated species was M. gordonae and 
these isolates had no clinical significance. Further study is necessary to confirm our findings 
and to explore the association between COPD, bronchiectasis and pulmonary NTM isolation, 
including follow-up of patients to find out more about NTM isolation and progression to NTM 
disease and accelerated lung function decline in COPD.
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Abstract
The incidence of Mycobacterium malmoense infections, compared to other nontuberculous 
mycobacteria (NTM) has increased since 1980, especially in northern Europe. Based on 
various epidemiological and clinical reports outside northern Europe, there is a wide 
distribution of these infections. Infections with M. malmoense cause pulmonary disease 
comparable with tuberculosis (TB). The main extra-pulmonary disease type is paediatric 
cervical lymphadenitis. M. malmoense isolates are clinically significant in about 70-80% of 
patients. Like other NTM infections, M. malmoense is often found in patients with chronic 
obstructive pulmonary disease (COPD) and may cause serious morbidity and mortality when 
inadequately treated. The best treatment consists of a 2-year regimen with rifampicin and 
ethambutol. The literature on infections with M. malmoense is reviewed with respect to 
epidemiology, clinical presentation, treatment and outcome.
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Introduction
Since Koch discovered Mycobacterium tuberculosis in 1882, a range of mycobacterial 
species have been identified. They can be divided into M. tuberculosis complex, M. leprae, 
and atypical mycobacteria or nontuberculous mycobacteria (NTM). NTM are also known 
as environmental mycobacteria due to their presence in natural water and soil.1-2 NTM are 
transmitted to humans mainly from environmental sources (aerosols, ingestion). Person-to-
person transmission, or transmission from animal sources has not been proven.2-3 NTM can 
be subdivided in at least 120 different species with different rates of evolutionary divergence, 
varying biochemical characteristics, clinical presentation, clinical relevance in human beings 
and susceptibility to anti-mycobacterial agents. Many NTM have proven to be clinically 
relevant, stimulating interest for these NTM in recent years.7 
The diagnostic criteria set in a Statement by the American Thoracic Society (ATS)8 and those 
published by the British Thoracic Society (BTS)12 are generally used to differentiate between 
true NTM infection, pseudo-infection and contamination. This differentiation is made using 
clinical, radiological and microbiological features (see Box). A diagnosis of  infection with 
an NTM – correct or incorrect - leads to a long period of treatment with anti-mycobacterial 
drugs.8,12-13 The ATS and BTS also provide evidence-based guidance on treatment of NTM 
infections. Increasing numbers of clinical NTM isolates have been observed in recent years.14-
15 M. malmoense, first isolated in 1954 from patients close to the Swedish city of Malmö, 
is one of the NTM that, according to the ATS and/or BTS criteria, is frequently considered 
clinically relevant. First described as a respiratory tract pathogen in 1977 by Schroder & 
Juhlin,16 M. malmoense is now considered the second most serious pathogen after M. avium 
complex in northern Europe.8,12,14 However, few references on M. malmoense are found in 
NTM treatment guidelines.8 
The present paper reviews the current knowledge of infections with the NTM M. malmoense 
with respect to epidemiology, clinical presentation, laboratory diagnosis, treatment and 
outcome.
American Thoracic Society Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan that 
shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. (If the results 
from the initial sputum samples are nondiagnostic, consider repeat sputum AFB smears and 
cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous 
inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic 
features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that 
are culture positive for NTM.
Box: Summary of the 2007 American Thoracic Society diagnostic criteria
Abbreviations: CT = Computed tomography, HRCT = High resolution computed tomography
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Methods
We performed a literature search using Pubmed (National Centre for Biotechnology 
Information [NCBI]; http:// www.pubmed.gov). Medical Subject Headings (MeSH) 
terms “atypical mycobacteria” and “atypical mycobacterium infection” combined with 
“Mycobacterium malmoense” were used. The literature was searched from 1954 (when M. 
malmoense was firstly isolated) to 2007. Articles that used data derived from a mycobacterial 
reference laboratory, with a known and well defined catchment area9 were used for 
describing epidemiology. The term notification is used to describe the number of isolates, 
irrespective of its clinical significance. Randomised clinical trials, retrospective medical file 
studies, and reports describing four or more patient cases were included for summarising 
clinical symptoms and signs, treatment and outcome. 
Results
Epidemiology 
Ten articles were identified that report on a well defined region and are therefore included 
to describe the epidemiology. Several studies described a rise in the notification of M. 
malmoense infections between 1980 and 1994 in northern Europe (table 1).  The increase 
observed in England and Wales was more obvious than for M. kansasii and M. xenopi, making 
M. malmoense the secondmost frequently occuring NTM after M. avium in this region.17 
Moreover, M. malmoense was the secondmost frequently occurring NTM infection after M. 
avium complex in 117 non-HIV patients between 1995 and 1999 in an urban community in 
the UK.18 A specific geographic clustering of M. malmoense infections was observed in the 
specific region of Lothian (Scotland), while the number of M. malmoense isolates as part of 
the total NTM isolates was not different for Lothian in comparison with the rest of Scotland.9 
Except for some case reports of (extra) pulmonary infections,19-22 studies concerning M. 
malmoense were rare outside northern Europe until the mid-1990s. 
The first retrospective study from a reference laboratory showed an increase in notification 
between 1993 and 1995 from 11 to 27 in the USA.10 In the mid-1990s, a specialised laboratory 
in Italy received 15 M. malmoense isolates in 25 months.23 An increase in the number of M. 
malmoense isolates was described in a recent multi-country retrospective survey in Europe. 
In the period 1985-1990, 102 M. malmoense isolations were reported (1.7% of all the isolated 
NTM), and within the period 1991-1996 this number was 463 (2.2%). This increase was mainly 
attributable to a rise of M. malmoense isolation outside the UK, especially Switzerland and 
Germany.15 In the Netherlands, an average of 13 patients with M. malmoense isolates were 
notified annually in the period 2000 to 2006 (D. van Soolingen, Personal Communication, National 
Mycobacteria Reference Laboratory).
Despite some anecdotal reports from Scotland,24 man-to-man transmission of M. malmoense 
is not reported . A molecular epidemiology study performed in Scotland, found no evidence 
for transmission between patients.25 Environmental sources are not well defined, although 
the isolation of M. malmoense from water and soil is described.1, 26
Clinical Presentation
The clinical presentation of pulmonary M. malmoense disease sometimes mimicks pulmonary 
disease caused by M. tuberculosis with productive cough, dyspnoea, fever, haemoptysis, 
and weight loss.4, 10 Radiological features of pulmonary M. malmoense infections are mostly 
impressive cavitation and/or infiltration (Figure 1 and 2).4, 6, 11, 27 Most patients with pulmonary 
infection are males, with a mean age of 60 years.5-6, 11 Extra-pulmonary M. malmoense 
infection is rare, except for lymphadenitis in children and tenosynovitis.28-30 In England and 
Wales, in the study period 1982 to 1994, 83% of the M. malmoense infections presented in 
the lung, 7.7% in lymph nodes, 4% in the skin or wounds and another 3.4% as abscesses.28
In Sweden, 221 cases of M. malmoense infection were described , identified between 1968 
and 1989, of which 21% were of extra-pulmonary origin.6 A detailed review of the extra-
pulmonary cases has been presented by Zaugg et al. who concluded that extra-pulmonary 
infection with M. malmoense is rare and that dissemination is only observed in patients with 
severely impaired immunity.29
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Figure 1 Chest radiograph showing a cavity in the left 
upper lobe in a patient with positive sputum smears with 
a cultured M. malmoense in a patient suffering COPD. 
(source: Hospital Drachten, the Netherlands. With 
permission).
Figure 2 Computed Tomography scan of 
the thorax of the same patient as in figure 
1 showing widespread cavitation in the left 
upper lobe bullous changes in the right 
lung as well around the cavity. (source: 
Hospital Drachten, the Netherlands).
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In a Danish survey, M. malmoense was found to be clinically relevant in 83% of patients 
with M. malmoense isolates.11 The clinical significance of M. malmoense in the USA was 
remarkably lower,10 than in studies performed in northern Europe. In Italy, 10 of 15 patients 
from whom M. malmoense isolates were obtained had a clinically significant infection.23 The 
clinical relevance of M. malmoense isolation in different studies is mentioned in Table 2.
The prevalence of underlying diseases in M. malmoense infections is summarized in Table 
3. Infections with M. malmoense are prevalent among patients with pre-existing pulmonary 
disease, especially chronic obstructive pulmonary disease (COPD) (26-45%).11, 19 In the BTS trial 
55% of the studied patients with a clinically significant M. malmoense infection had a history 
of chronic bronchitis, emphysema or asthma and old, healed TB. In the urban community of 
Leeds, UK, infection by M. malmoense was especially prevalent among COPD patients, more 
so than other NTM, including M. avium and M. kansasii.19 Two patients with clinical symptoms 
due to HIV infection in a group of seven patients with clinically relevant infection were found 
in the USA.10 Bollert et al.9 reported one patient with AIDS and 19 HIV-negative patients with 
clinically relevant M. malmoense infections. In Italy, two of 10 patients with clinically significant 
M. malmoense infection had AIDS; both were suffering from cavitary pulmonary disease.23 
Case reports describing M. malmoense infections in HIV-positive patients are uncommon, but 
dissemination has been reported.29, 31, 32 Immune suppression due to chronic steroid use has 
been described in 3.5-13% of patients with M. malmoense infection (Table 3). 
Author (reference) Study area Study period Notification (year)
Banks, 19854 Wales 1978-1983 Total: 46
Jenkins, 198528 England and Wales 1954-1984 every year n=1-4 (1954-1980)
10 (1981)
31 (1984) 
France, 198724 Scotland 1982-1984 Total: 20
Katila, 19915 Finland 1971-1987 Total: 66
Henriques, 19936 Sweden 1968-1989 19 (1968-1977)
22 (1978-1980)
39 (1981-1983)
70 (1984-1986)
71 (1987-1989)
Bollert, 19959 Scotland 1990-1993 Total: 95
Lamden, 199617 England and Wales 1982-1994 10 (1982)
80 (1993)
Buchholz, 199810 USA 1993-1995 11 (1993)
35 (1994)
27 (1995)
Thomsen, 200211 Danmark 1995-1996 Total: 20
Henry, 200418 Leeds 1995-1999 3 (1995)
5 (1996)
6 (1997)
2 (1998)
5 (1999)
Table 1 Epidemiology: notification of M. malmoense (total number of positive isolates irrespective of 
clinical significance)  in different geographical areas. 
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Author (reference) Patients (n) Criteria Clinical significance
Banks, 19854 34 Repeated isolates
compatible symptoms & signs  
84%
Katila, 19915 66 Unclear 81%
Henriques, 19936 221 ATS 70%
Bollert, 19959 41 ATS 75%
Buchholz, 199810 60 ATS 10%
Thomsen, 200211 20 Modified ATS Bacteriological criteria: 83%
Radiographic criteria: 100%
Clinical criteria: 88%
Table 2 Clinical significance of M. malmoense in different studies. The criteria for determining clinical 
significance used in the different studies are presented in column 3. ATS= criteria as determined by the 
American Thoracic Society (6). Modified ATS: bacteriological criteria were modified to criteria used in 
Denmark (not further specified).
Authors Patients (n) % Male HIV
Immune 
suppression COPD Other co-morbidity
Banks, 
19854
34 60 unknown 12% (chronic 
steroids n=3; 
immunosupp. 
n=1)
47% Bronchiectasis: 6%
Coal workers 
pneumoconiosis: 9%
History PTB: 9%
Peptic ulcers: 36%
France, 
198724
20 65 unknown 10% (chronic 
steroids)
45% Pneumothorax: 10%
TB, PF, aspergillosis, 
pneumoconiosis: 
all n=1
Malignancy: 20%
Peptic ulcers: 40%
Henriques, 
19936
221 53 unknown 13% (chronic 
steroids)
unknown History PTB: 33%* 
(12% also PD) 
PD alone: 28%*
Malignancy: 11%*
Leukemia: 1.5%*
Lamden, 
199617
470 unknown Unknown 3.5% unknown unknown
Bollert, 
19959
41 unknown Positive: n=1 unknown unknown unknown
Buchholz, 
199810
736 62 Positive: n=2 
(both active AIDS)
No n=2 
(33%)
History of PTB n=2 
(33%)
Thomsen, 
200211
13 69 None None n=6 Cancer n=1
BTS, 
200333
106 62 Excluded 13% (condition?) CB/
Emph/A: 
26%
old/cured PTB: 21%
Bronchiectasis: 1%
Henry, 
200418
18 unknown Excluded unknown 44% Bronchiectasis: 5%; 
History PTB: 10%; 
Table 3 Age, HIV, immune suppression and co-morbidity among M. malmoense infected patients. PTB= 
pulmonary tuberculosis, PD = pulmonary disease, PF = pulmonary fibrosis. * = Co-morbidity in patients 
with pulmonary M. malmoense infection (n=131). 
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Labaratory diagnosis
Although acid-fast bacilli (AFB) smear microscopy is still the starting point, the laboratory 
diagnosis of NTM disease has changed dramatically over the past two decades. The recent 
introduction of liquid culture systems has substantially shortened the time to detection for 
NTM, as well as increasing sensitivity. The disadvantage of these liquid culture systems is that 
they do not allow quantification and assessment of colony morphology.8
Identification of NTM has long been based on growth rate, colony morphology and a series 
of biochemical tests performed on live cultures, combined with, or substituted for, cell wall 
fatty acid composition analysis.7, 8 The advent of molecular tools, especially 16S rDNA gene 
sequence analysis, has improved and accelerated this identification process. In addition, 
these techniques have shed new light on mycobacterial taxonomy.7, 8, 32 
The differences (two basepairs [bp]) between M. malmoense and M. szulgai have long 
been considered one of the drawbacks of 16S sequencing. However, one bp difference can 
result in important phylogenetic differences. Furthermore, sequencing is still expensive and 
technically demanding, and its use is therefore limited to large or reference laboratories. 
Nevertheless, 16S sequencing and high-performance lipid chromatography, both widely 
used for mycobacterial identification, can be successfully applied to identify M. malmoense.8 
To provide molecular identification suitable for use in a clinical setting, line probe assays 
have been developed that use DNA probes rather than sequencing for identification of 
mycobacteria. A multitude of commercial line probe asays is now available, most of which 
include M. malmoense-specific probes.
The in vitro drug susceptibility testing (DST) of M. malmoense has not been found to be 
associated  with response to treatment.6, 33-35 The only published correlation linked ethambutol 
(EMB) resistance to treatment failure of a 2-year rifampicin (RMP) and EMB based regimen.33 
However, in vitro resistance to EMB and RMP, tested separately, has been observed in strains 
susceptible to a combination of the two drugs.36 
Management 
Current guidelines recommend that treatment for pulmonary M. malmoense infections 
consists of a 18-24 months regimen with EMB and RMP.12 The ATS guidelines published in 2007 
suggest a three drug regimen with RMP, isoniazid (INH) and EMB8. Banks et al.4 and France 
et al.24 concluded that adding EMB to other first-line drugs improved outcome, supported by 
a synergistic effect with EMB observed in in vitro tests. Patients receiving second-line drugs 
had poorer outcome related to drug toxicity and poor patient adherence.6, 33 According to a 
special research committee of the BTS, a 2-year regimen of RMP and EMB is better tolerated 
than RMP and EMB combined with INH. This recommendation is based on a randomised 
clinical trial in 106 non-HIV patients with pulmonary M. malmoense infection.33, 35 Ten per cent 
of the patients remained culture-positive after 2 years of treatment with RMP and EMB, with 
or without INH. Henry et al.18 found a significant association between appropriate treatment 
and a successful outcome in non-HIV patients with clinically relevant pulmonary and extra-
pulmonary NTM infections, including infections by M. malmoense (n=18). Appropriate 
therapy was defined as adherence to the BTS criteria and treatment for 2 years with RMP + 
EMB for M. malmoense. Forty-four per cent received appropriate therapy. In this group, 25 % 
died, in contrast to 80% deaths in the group treated for less than 12 months. 
Furthermore, the involvement of two or more lung zones is found to be an independent 
predictor of death.33 A recently published in vivo clinical trial studying the combination of RMP 
+ EMB with quinolones (ciprofloxacin) or macrolides (clarithromycine [CLM]) has not shown 
improved outcome of these adjunctive treatment modalities in M. malmoense infections. 
Because of a higher observed “all-cause death rate” among patients treated with RMP + EMB 
and ciprofloxacin and the observation of more significant side-effects among RMP + EMB and 
CLM treated patients, first line treatment for pulmonary M. malmoense disease is still RMP 
+ EMB.37
Discussion 
An increase in the number of clinical M. malmoense isolates has been observed, especially in 
northern Europe, since the 1980s. This increase is more pronounced for M. malmoense than 
in other clinically significant NTM.14, 28 Possible explanations for this increase are: 1) changes 
in host defence mechanisms or a larger number of patients with impaired immunity; 2) 
increased awareness or focus of physicians on requesting mycobacterial sputum cultures; 3) 
selection within NTM due to environmental factors, for example differences in susceptibility 
to desinfectants used in tap water; 4) improved culture methods, e.g. liquid media; and 5) 
improved identification techniques for NTM.
In the early 1980s, reports of M. malmoense isolation were mostly from northern Europe, 
some suggesting regional clustering.38 The prevalence of M. malmoense outside northern 
Europe remains unclear with an increase in notification in the USA10 and the presence of 
M. malmoense in the environment of the Democratic Republic of Congo (former Zaire)22 
and Japan26 but absence of isolation in Ontario, Canada.39 Some geographically determined 
environmental niches (water reservoirs) or characteristics (temperature) may favour survival 
of the mycobacterium and thus transmission to humans.1, 2 Further molecular epidemiology 
studies are needed to search for environmental resources and transmission vectors for 
human infections.
Infections with M. malmoense cause considerable morbidity and mortality. Studies 
performed in northern Europe found clinically relevant infection (defined by fulfilment of 
the ATS diagnostic criteria or a modification of them) in over 70% of cases. Clinical relevance 
of pulmonary M. malmoense in the Netherlands is found to be over 80% as determined by 
a retrospective study and, in comparison with other NTM, the most relevant.40 In the USA a 
retrospective reference laboratory study found only 10% of clinical isolates to be clinically 
significant between 1993 and 1995, according to the ATS criteria.10 Confounding factors 
include differences between countries regarding indications for mycobacterial strains and 
cultures and variation in the assessment of clinical relevance. Differences in pathogenicity of 
M. malmoense between continents have not yet been studied. 
COPD, and especially emphysema, is frequently observed as an underlying condition in 
M. malmoense infections. The pathological conditions of COPD patients (impaired local 
immunity) probably favour infection with M. malmoense. It is not known if infection with 
M. malmoense occurs more frequently in severe COPD. The male predominance may be 
partly explained because, at least in the past, males more often suffer COPD and therefore 
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have a higher probability to be evaluated for, or to be infected by, NTM. While few cases of 
pulmonary M. malmoense infection have been described in HIV positive patients, in some 
epidemiological studies a considerable number of patients are found to be HIV positive,10, 23 
together with case reports describing M. malmoense dissemination in patients with HIV with 
advanced disease (CD4 count<100 cells/µl).31-32 Recent data suggest an underestimation of 
clinically relevant NTM infections among HIV-positive and HIV–negative patients in Africa.41 
Further study is therefore needed.
The BTS guidelines supply treatment guidance based on a solid randomized clinical trial that 
was designed also for M. malmoense infections, and they can therefore be recommended. 
Inadequate treatment of M. malmoense infections may cause significant mortality in COPD 
patients. In vitro evidence suggests increased susceptibility for a combination of RMP, EMB 
and CLM when compared to the standard treatment regimen of RMP and EMB33. There is no 
evidence that DST contributes to the choice of treatment regimen. However, in vitro testing 
may be helpful in choosing alternative drug regimens in treatment failure cases. To date, 
there is no evidence for the additional value of INH or CLM, for example in patients with 
treatment failure or relapse.37  
In conclusion, rising notifications of M. malmoense observed in different countries have 
been more obvious than those of other clinical relevant NTM, and it is responsible for clinical 
relevant disease, especially in COPD patients. Epidemiological studies remain important to 
assess a possible further increase in incidence. The incidence of clinically significant infections 
should be investigated in different countries. Genotyping of M. malmoense is of great value 
as a tool for studying epidemiology, as well as for identifying suspected sources of infection 
from the environment. While the only evidence based treatment is 18 months RMP and EMB, 
more studies are needed, including studies of other drug combinations.
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Abstract
Uncertainty exists about the clinical relevance of Mycobacterium malmoense isolation, 
especially in pulmonary samples. We therefore determined clinical relevance, treatment and 
outcome of M. malmoense isolation in the Netherlands.
A retrospective medical file study was conducted for all patients in the Netherlands from 
whom Mycobacterium malmoense had been isolated between January 2002 and January 
2006. Diagnostic criteria for nontuberculous mycobacterial (NTM) disease published by the 
American Thoracic Society (ATS) were used to determine clinical relevance. Treatment was 
compared with guidelines published by the British Thoracic Society.
In total, 51 patients were found from whom M. malmoense was isolated. Of these, 40 (78%) 
patients had pulmonary isolates and 32 (80%) of them met the ATS diagnostic criteria. Cavitary 
disease was most common (n=28; 88%). Patients with pulmonary disease were mostly males, 
with an average age of 56 years and pre-existing chronic obstructive pulmonary disease. 
Cervical lymphadenitis was the most common extrapulmonary disease type. Adherence to 
treatment guidelines was poor. A good clinical response to treatment was observed in 70% 
and 73% of patients treated for pulmonary and extrapulmonary disease, respectively.
In conclusion, M. malmoense is a clinically highly relevant NTM in the Netherlands causing 
serious pulmonary morbidity. Adherence to treatment guidelines is not satisfactory. 
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Introduction
First described as a respiratory tract pathogen in 1977 by Schröder and Juhlin,1 Mycobacterium 
malmoense is among the most frequently isolated and clinically relevant nontuberculous 
mycobacteria (NTM) in northern Europe.2-4 The environment is the suspected source 
of transmission of NTM to humans through aerosols and ingestion. Person-to-person 
transmission or transmission from animal sources has not been proven3, 5-6. The presence of 
NTM in the environment implies that a NTM cultured from a non-sterile body site, such as 
the respiratory tract, may result from contamination or occasional presence of the NTM in 
a sample. Hence, it is important to distinguish contamination from true NTM disease. The 
American Thoracic Society (ATS) has published guidelines to assist in this distinction.3 The 
clinical relevance of a NTM species can be quantified by assessing the percentage of patients 
with positive cultures of the respective NTM who meet the ATS diagnostic criteria. 
In the current study, we quantified the clinical relevance of M. malmoense isolation in the 
Netherlands between 2002 and 2006 by applying the ATS diagnostic criteria, and evaluated 
treatment and outcome.
 
Materials & Methods
Study subjects 
Patients were identified by reviewing the database of the Dutch National Institute for 
Public Health and the Environment (RIVM; Bilthoven, the Netherlands) for M. malmoense 
positive cultures. The RIVM is the national mycobacteria reference laboratory that provides 
identification and drug susceptibility testing for all hospitals in the Netherlands. We reviewed 
medical records of the identified patients from whom Mycobacterium malmoense was 
cultured between January 2002 and January 2006.
Study design and setting
The present study was a retrospective observational study concerning all patients with 
M. malmoense positive cultures identified at the RIVM. The Central Committee on Research 
involving Human Subjects, Arnhem-Nijmegen regional office (Radboud University Nijmegen 
Medical Center, Nijmegen, the Netherlands) approved the study. We recorded demographic 
data, clinical data, drug susceptibility, treatment and outcome. The 2007 ATS diagnostic 
criteria were used to determine clinical relevant infections (Box 1).3 
Treatment was compared with guidelines published by the British Thoracic Society (BTS): 
a NTM based treatment regimen was defined as consisting of rifampicin or rifabutin and 
ethambutol.7 An adequate response to treatment was defined as symptomatic improvement 
and reversion to at least three subsequent negative cultures. 
The RIVM subjected isolates of most patients to laboratory diagnosis. All patients’ isolates were 
subcultured in both liquid and solid media and identified using the Inno-Lipa Mycobacteria 
v2 (Innogenetics, Gent, Belgium) reverse line blot assay which has specific probes for M. 
malmoense. Prior to 2004, 16S rDNA gene sequencing (151bp hypervariable region A) was 
performed, after ruling out membership of the M. tuberculosis or M. avium complex using 
the AccuProbe assays (GenProbe, San Diego, USA). Remaining isolates were identified at local 
hospitals, by 16S sequencing.
Drug susceptibility was tested using the agar dilution method.8 Drugs included in the test 
panel were isoniazid, rifampicin, ethambutol, streptomycin, cycloserine, prothionamide, 
amikacin, ciprofloxacin, clofazimine, clarithromycin, and rifabutin.
Data analysis
Pearson Chi-squared and Fisher exact tests were used for statistical correlations.
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American Thoracic Society Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan 
that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. (If the 
results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB smears 
and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing 
mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more 
sputum or bronchial washings that are culture positive for NTM.
Box 1: SuMMArY oF The 2007 AMerICAN ThorACIC SoCIeTY dIAgNoSTIC CrITerIA
Results
M. malmoense was isolated from 51 patients in the study period. In total, 40 (78%) patients 
had pulmonary isolates; in 11 (22%) cases these were of extra-pulmonary origin. No patients 
in the study group were HIV-infected.
During the study period, no increase in notification of M. malmoense isolation was observed 
each year.
Pulmonary isolates
Of all 40 patients with pulmonary M. malmoense isolates, 32 (80%) met the ATS diagnostic 
criteria and were likely to suffer M. malmoense lung disease. The baseline patient 
characteristics are detailed in Table 1. 
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ATS criteria met ATS criteria not met Total P value
N 32 8 40
Males 21 (66) 7 (88) 28 0.67
Mean age (range) 56 (28-81yr) 57 (33-83yr) 56 (28-83yr) 0.84
Pre-existing pulmonary disease 26 (81) 7 (88) 33 0.57
COPD 21 (66) 5 (63) 26 0.59
Prior TB 2 (6) 2 (25) 4 0.18
AFB smear positive 27 (84) 2 (25) 29 0.03
Cavitary lesion 28 (88) 1 (13) 29 < 0.001
Nodular lesion(s) 4 (13) 1 (13) 5 0.74
Table 1: Baseline characteristics of patients with a Mycobacterium malmoense isolates
Data are presented as n or n (%). ATS: American Thoracic Society; COPD: Chronic obstructive pulmonary disease; 
TB: tuberculosis; AFB: acid fast baccilli
The predominant patient profile is a male with pre-existing pulmonary disease, mainly chronic 
obstructive pulmonary disease (COPD). The seven patients without a previous diagnosis of 
pre-existing pulmonary disease were mostly smokers, with radiographic features suggestive 
of pulmonary disease. Most patients reported productive cough (n=37; 93%), weight loss 
(n=24; 60%), and fatigue (23; 58%). Night sweats (n=10; 25%), hemoptysis (n=7; 8%) or fever 
(n=11; 28%) were infrequently reported. Only patients who reported weight loss were more 
likely to meet the ATS diagnostic criteria (p=0.048; odds ratio 7.333; 95%CI 1.072-50.145). In 
the group of patients that did not meet the ATS diagnostic criteria, four failed to meet the 
bacteriological criteria (three because only one sputum sample was collected) and four failed 
to meet the bacteriological and radiological criteria. Overall, 75% (n=24) of the 32 patients 
that met the ATS criteria for pulmonary NTM disease presented with cavitary lesions visible 
on chest radiographs. Additional computed tomography scanning revealed 4 extra cases of 
cavitary disease (total n=28; 88%), not identified as such using plain chest radiographs. Two 
patients presented with multiple nodular opacities on chest radiograph; two had a single 
pulmonary mass. 
The 30 patients who met the ATS diagnostic criteria for pulmonary NTM disease started 
treatment. Figure 1 summarizes treatment and outcome in the study group. The mean 
duration of antimycobacterial treatment was 12 months (range 1–26 months). Macrolides 
were added in 22 patients (18 clarithromycin, 4 azithromycine; 92%), fluoroquinolones in 
six patients (four ciprofloxacin, two moxifloxacin; 25%). Nine patients received therapy for 
presumed tuberculosis, prior to the diagnosis of NTM disease, for a mean duration of 48 days 
(range 2-123 days), and completed a NTM based regimen afterwards. Six patients with M. 
malmoense pulmonary disease only received a complete first-line tuberculosis treatment. 
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Of the 30 patients treated, 21 (70%) patients showed an adequate response, five (17%) 
suffered a failure or relapse (mean time to relapse 13 months, range 5-24 months) and four 
(13%) died (Figure 1). Although the percentage of patients with an adequate response was 
lower in those receiving macrolide containing regimens (43 versus 63%), this difference 
was not statistically significant (p=0.344). The mean duration of treatment among patients 
who later relapsed was shorter than for patients with an adequate response, although not 
significantly (320 versus 358 days; p=0.709). The frequency of adequate response was not 
significantly different between patients treated with a tuberculosis-based regimen and 
those treated with a NTM regimen (p=0.260). Two patients who met the ATS criteria refused 
treatment: one patient died, the other showed progressive disease. Follow-up of patients 
not meeting ATS diagnostic criteria was uneventful; no more positive cultures were recorded. 
Symptoms regressed in absence of antimycobacterial treatment.
Six (20%) patients received the 24 months of rifampicin and ethambutol regimen based on 
the BTS trials. This did not affect the percentage of patients with an adequate response (83% 
for the BTS regimen versus 71% for other regimens; p= 0.426). 
Contact-tracing studies were initiated for two patients with pulmonary M. malmoense 
isolates; both were presumed to have pulmonary tuberculosis. Some contacts received 6 
months of isoniazid, based on a tuberculin skin test conversion.
In the current study, one case of disseminated M. malmoense disease was noted in a patient 
who received immunosuppressive treatment after kidney transplantation. He presented with 
pulmonary M. malmoense disease, which extended to histologically and bacteriologically 
proven lymphadenitis and mediastino-esophageal fistula, with blood cultures yielding M. 
malmoense. Interestingly, this patient had strong epidemiological links to a patient diagnosed 
with smear positive pulmonary M. malmoense disease one year before. 
Figure 1: Frequency, treatment and outcome of pulmonary M. malmoense disease in the Netherlands 
between 2002 and 2006.
NTM based: treatment given to treat nontuberculous mycobacteria; TB based: group of patients treated only for a presumed 
tuberculosis infection; ATS+: fulfilment of the criteria of the American Thoracic Society; PD: progressive disease.
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Extra-pulmonary isolates
Eleven patients had extra-pulmonary M. malmoense isolates; we noted 10 cases of 
cervicofacial lymphadenitis, including two in elderly patients. One case of tenosynovitis of 
the second and third digit of the right hand was observed in a plant handler with a history of 
multiple wounds to the right wrist. He had an adequate response after surgical debridement 
followed by a macrolide based regimen of 13 months’ duration. The eight pediatric cases of 
lymphadenitis were three boys and five girls without predisposing conditions, with a mean 
age of 36 months (range 22-46 months). All presented with painless cervical or submandibular 
swelling, without fever or other symptoms. Surgical excision was the most frequent treatment 
and resulted in an adequate response in all patients. One of the elderly patients had a relapse 
after surgery; the other had an adequate response. Overall, eight (73%) patients with extra-
pulmonary isolates had an adequate response after the initial therapy.
In vitro drug susceptibility testing was performed on the primary isolates from 46 patients. 
Isolates were resistant to isoniazid (all), streptomycin (70%), amikacin (70%), ciprofloxacin 
(61%); intermediately susceptible (39%) or resistant (46%) to ethambutol; and susceptible 
to rifampicin (72%), rifabutin (96%), clarithromycin (all), cycloserine (98%), prothionamide 
(96%) and clofazimine (all). Relapse or treatment failure among patients with pulmonary 
M. malmoense disease was not associated with in vitro rifampicin or ethambutol resistance 
(p=0.327 and p=0.405 respectively).
Discussion
M. malmoense is one of the most clinically relevant NTM in the Netherlands. Overall, 80% 
of patients with pulmonary isolates met the ATS diagnostic criteria, compared to 21 (47%) 
relevant infections among 45 patients with pulmonary M. xenopi isolates, and 11 (73%) 
among 15 patients with pulmonary M. szulgai isolates.9, 10 We observed M. malmoense disease 
exclusively in HIV-negative patients, which is in contrast to M. avium, M. kansasii, M. xenopi 
and M. szulgai.3, 9-10 Patients were mainly males with pre-existing pulmonary disease. The ATS 
diagnostic criteria were designed for infections with M. avium, M. kansasii and M. abscessus; 
they may be less applicable to M. malmoense. Because of the high degree of true pulmonary 
M. malmoense infections observed, judgment on the clinical relevance of pulmonary M. 
malmoense isolates could probably be based on less strict criteria, as is advocated for M. 
kansasii,3 to prevent a prolonged period of inadequate treatment. The high degree of clinical 
relevance is in accordance with previous observations from northern Europe, varying from 
70% to 84% using either ATS criteria or a modification of these criteria.11-14 
Interestingly, a dramatically lower clinical relevance of 10% was found in a retrospective case 
study of 73 patients in the USA.15 There is no explanation for this difference; however it suggests 
less pathogenic strains of M. malmoense in northern America compared with northern Europe. 
There are no known bacterial virulence factors for M. malmoense. Phylogenetically related 
M. szulgai and M. kansasii, both of which are suggested to be among the most pathogenic 
NTM 3, 9 are known to harbor a region of difference 1-like genetic element (including esat-6 
and cfp-10 genes) which is a well-known virulence factor for M.tuberculosis.16 M. malmoense, 
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however, lacks this element.17 To date, immunological studies have focused on M. avium and 
M. abscessus,18-19 rather than M. malmoense. Studies of M. malmoense pathogenesis and 
virulence in murine models are warranted, as are studies on the role of host genetic factors 
in M. malmoense disease. 
In a recently published retrospective study of the prevalence of all NTM in Ontario, Canada, 
between 1997-2003, M. malmoense was not isolated.20 This observation is in contrast with the 
increase in M. malmoense notification in Europe since 1980, including increasing numbers of 
countries reporting isolation of M. malmoense.21 This contrast suggests environmental niches 
favouring transmission to humans in Europe. Whether this observation can be linked with the 
lower clinical relevance observed in the United Sates needs to be studied.
Human transmission has never been proven, even in a setting of geographic clustering of 
cases. In a study published by Doig et al., small differences observed using pulsed-field 
electrophoresis were sufficient to show a lack of correlation between strain type and 
epidemiological or patient characteristics, making person-to-person spread unlikely.22 
The BTS treatment guidelines for pulmonary M. malmoense disease were not well adhered 
to, including choice of antimycobacterial therapy and duration of therapy. Treatment of M. 
malmoense disease was often preceded by or consisted only of tuberculosis treatment. This 
observation reflects the similar clinical presentation of pulmonary M. malmoense and M. 
tuberculosis complex infection and is a cause of concern. Increasing the use of PCR to rule 
out M. tuberculosis, providing a quick and definite NTM diagnosis, will probably decrease 
morbidity and mortality and prevent initiation of unnecessary contact tracing studies. 
Although hampered by our limited study group size and duration of follow-up, successful 
clinical response (83%) in the current study in the optimally treated group is comparable with 
a 75% successful outcome found by Henry et al.23 The failure and relapse rates found in the 
recently published BTS trial (12% in the group treated with R and E, 5% in the group treated 
with R and E combined with clarithromycine or ciprofloxacin) are lower compared to the rate 
found in our study (17%).24 The shorter mean duration of antimycobacterial therapy probably 
negatively influenced treatment outcome in our population.
The mortality rate (13%) found among adequately treated patients in the present study is 
comparable to that found by Banks et al (15%),11 and Henry et al (11%).23 The NTM disease-
related mortality after 5 years of follow-up was found to be low (3,6%).24 Mortality has 
been related to the length of delay between diagnosis and start of the treatment, while the 
occurrence of relapse has previously been associated with total time span of treatment.11 
Other factors suggested to independently affect mortality are in vitro resistance to ethambutol 
and the involvement of more than one lung zone.15 In our study population, there was no 
significant association between ethambutol resistance and treatment failure. 
The recently published BTS trial showed no additional benefit of adjunctive clarithromycin 
or ciprofloxacin over the 24-month regimen of rifampicin and ethambutol for pulmonary M. 
malmoense disease. The addition of clarithromycin even led to more side-effects.24 These data 
are clinically important considering the extent of adjunctive macrolide and/or fluorquinolone 
use in our study group. 
The frequency and types of extrapulmonary disease in our study are similar to those found in 
a survey in Sweden, in which 21% out of 221 patients had extra-pulmonary isolates, mainly 
lymphadenitis.14 Pediatric cases of cervicofacial lymphadenitis are most frequent and tend 
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to affect children in a limited age range, which may be related to environmental exposures 
specific to this age category,25 or the state of development of the immune system in children. 
Contrary to pulmonary disease, M. malmoense lymphadenitis is a relatively benign condition. 
Surgery is considered to be the optimal treatment and yields good results [3, 26].3, 26
Tenosynovitis due to M. malmoense is rare, although case reports are available in the 
international literature.27 Extra-pulmonary infection with M. malmoense is rare and 
dissemination is only observed in patients with severely impaired immunity, although rarely 
in HIV/AIDS.
In conclusion, pulmonary Mycobacterium malmoense isolation is clinically relevant in 80% 
of all patients in the Netherlands, reflecting a level of virulence unmatched by other NTM 
species. Pulmonary disease resembling tuberculosis, and pediatric lymphadenitis are the 
most common types of M. malmoense disease. Some patients are incorrectly treated for 
tuberculosis for a lengthy period. We recommend the use of molecular diagnostic tools 
for every sample positive for mycobacteria to enable quick initiation of adequate therapy. 
Treatment outcome is relatively favourable when compared to other NTM infections. Future 
studies are necessary to optimize treatment regimens and to discern host and pathogen 
factors determining virulence and transmission to humans. 
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Abstract
Nontuberculous mycobacteria (NTM) are opportunistic pathogens that arewidely present in 
our environment. Human transmission of NTM infections has never been proven.
We report a perfect storm scenario for NTM human transmission in which an acid fast bacilli 
(AFB) positive, coughing patient, diagnosed with cavitary Mycobacterium malmoense lung 
disease, is in close contact with an immunocompromised patient who was 11 months after 
the diagnosis of the AFB positive patient, found to have also a M. malmoense lung disease. 
However, multi-locus sequence typing and genotyping results including sequencing of the 
hsp65 gene made human transmission in this case highly unlikely.
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Introduction
Nontuberculous mycobacteria (NTM) are opportunistic pathogens that are widely present in our 
environment, i.e. in the soil and in natural and processed water. This group of organisms, with varying 
biological properties and clinical relevance, has gained notoriety over the past two decades due to their 
capability to cause severe disease in patients with immunodeficiency and/or chronic lung disease.1 
Despite their rising isolation frequency and growing clinical importance, NTM infections receive little 
scientific or public health attention. This partly results from the dogma that these NTM infections are 
not transmitted from male-to-male.1
During our previous research of Mycobacterium malmoense infection in the Netherlands,2 we studied 
two patients with M. malmoense pulmonary infection with a strong epidemiological link. Human 
transmission was suspected because an acid-fast bacilli (AFB) smear positive patient was in close contact 
with an immunocompromised patient. Herein, we present details of the cases and the results of the 
molecular diagnostics that were performed. The patients gave informed consent; ethical approval was 
not required for this retrospective study.
The cases 
Case 1. A 38- year old male with a medical history of chronic obstructive pulmonary disease 
and spontaneous pneumothorax reported to the respiratory physician with progressive 
dyspnoea, productive cough, fever, night sweats, malaise and weight loss. A chest radiograph 
revealed infiltrates with cavities in the upper lobes. Laboratory diagnostics showed a raised 
erythrocyte sedimentation rate (90mm/h) and leukocytosis (white blood cell count 22.4 
cells/mL); serological tests for HIV were negative. Three sputum smears were negative for 
AFB on direct microscopy. Bronchoalveolar lavage was performed, which was positive for 
AFB on direct microscopy. A regimen of isoniazid, rifampicin, ethambutol and pyrazinamide 
was initiated, based on a presumptive diagnosis of pulmonary tuberculosis. Later, sputum 
appeared to be positive for AFB. All corresponding cultures yielded M. malmoense, identified 
by Inno-LiPA Mycobacteria v2 reverse line blot assay. Since the patient met the ATS diagnostic 
criteria for clinical disease1 the regimen was changed to 24 months rifampicin, ethambutol 
and clarithromycin and the patient slowly improved.
Case 2. 11 months after the diagnosis was made in patient one, a second patient was 
diagnosed with M. malmoense disease in the same hospital. This patient, a 59-year old 
male, had a history of kidney transplantation and subsequent immunosuppressive treatment 
with cyclosporine and prednisone. He presented with productive cough, malaise, fever and 
weight loss. Erythrocyte sedimentation rate was 110mm/hr and white blood cell count was 
8.5 cells/mL. A chest computed tomography scan revealed an infiltrate with cavitation in 
the left upper lobe and mediastinal lymphadenopathy. A transbronchial biopsy showed 
granulomatous inflammation with central necrosis and visible AFB on histological examination. 
Sputum samples revealed AFB on direct microscopy and corresponding cultures, and two 
simultaneously obtained blood cultures yielded M. malmoense. A regimen of rifampicin, 
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ethambutol and clarithromycin was initiated; owing to clarithromycin intolerance, this drug 
was changed to ciprofloxacin. After initial progression of disease, including sepsis, progressive 
pulmonary infiltrates and spontaneous rupture of a nectrotizing mediastinal lymph node to 
the esophagus, the patient recovered slowly. Both patients completed 24 months of drug 
therapy and have remained culture negative during 2 years of follow-up. Patient 2 died after 
the 2 year follow-up period due to a Grawitz tumor.
 
Epidemiological investigation revealed that the two patients were acquainted and had 
intensive contact because they very regularly met in the same bar. The first patient worked in 
a flower bulb processing factory. Isolates of both patients, as well as unrelated patients from 
the same region and bordering regions, were subjected to genotyping by repetitive element 
(rep)-PCR typing. The results were confirmed using amplified fragment length polymorphism 
(AFLP) typing as described previously.3-4 Rep-PCR typing revealed 97.4% similarity between 
isolates of both patients, suggesting they were possibly the same single strain. However, 
this same (>97% similarity) pattern was also observed from the M. malmoense isolate of an 
elderly woman with pulmonary M. malmoense disease living in a nearby city; this patient was 
not epidemiologically related. Other strains from nearby and more distant regions, as well 
as from the same region though a later period, revealed distinct patterns by rep-PCR typing 
(Figure 1A). However, AFLP typing showed that the isolates of both patients had only 90% 
similarity. AFLP included the strain of a patient with pulmonary M. malmoense disease from 
the neighbouring region (05-1477) in the cluster with isolates of both our patients (Figure 
1B). We subsequently sequenced the 16S rDNA gene, 16S-23S internal transcribed spacer 
(ITS) as well as partial hsp65 and rpoB genes, as previously described.5 The isolates of both 
patients had identical 16S, ITS and rpoB sequences; the 441bp Telenti-fragment of the hsp65 
gene showed 2 base pairs difference between both isolates.6
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Figure 1: Gene sequencing results of the isolates of the patients described including related strains 
isolated from other patients.
1A: Typing results obtained by rep-PCR (DiversiLab, BioMerieux). 
85
No human transmission of M. malmoense
Figure 1: Gene sequencing results of the isolates of the patients described including related strains 
isolated from other patients.
1B: Amplified Fragment Length Polymorphism typing results.
Note: 04-1708 is the strain isolated from patient 1, 05-1634 was isolated from patient 2; 97.4% similarity is calculated 
between the two using rep-PCR (figure 1A). 90% similarity is calculated between the two using AFLP (figure 1B). 
Strain 05-1681 was isolated from an elderly woman with pulmonary M. malmoense disease in a nearby city, 04-817 
was isolated from a child with lymphadenitis in the same region; 05-1477 was isolated from a patient with pulmonary 
M. malmoense disease in a neighboring district. More distantly related 09-142 and 05-1401 were isolated in the 
same region, but four years later, and in a region in another part of the country, respectively. Strain 05-1473 is an M. 
fortuitum isolate used as an outgroup; M. smegmatis mc2-155 and M. marinum 2000-01053 are control strains.
Discussion
Although there is a strong epidemiological link between both patients with a perfect scenario 
for human transmission (an AFB positive and coughing source in close contact with an 
immunocompromised receiver), the results of AFLP and the hsp65 gene sequences, showing 
two base-pairs difference between the strains of both patients, render human transmission 
in this case unlikely. Cases of NTM human transmission have been suggested previously, as 
was reviewed by Wolinsky.7 One setting showed some similarities to ours with two brothers 
who developed pulmonary Mycobacterium kansasii disease, with an interval of 1 year.8 Still, 
human transmission of NTM has, however, never been proven. 
The interpretation of genotyping results in order to make definite conclusions about human 
NTM transmission is complicated: even if both strains would have been fully identical by 
the methods described, this cannot rule out the possibility of infection from an identical 
environmental reservoir. The similarity with other strains from the same region (Figure 1) 
suggests presence of a local ecotype. If local ecotypes exist, as our typing data suggests, the 
environmental source need not even have been identical; they might have just been infected 
in the same region. In conclusion, we couldn’t establish human transmission in this case of an 
AFB positive and coughing source in close contact with an immunocompromised receiver.  
7
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Mycobacterium genavense in the 
Netherlands: an opportunistic pathogen 
in HIV and non-HIV 
immunocompromised patients. 
An observational study in 14 cases.
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M.J. Boeree, and D. van Soolingen
Clin Microbiol Infect 2012; 19: 432-437
90
Chapter 8
Abstract
Mycobacterium genavense is an opportunistic nontuberculous mycobacterium previously 
mostly associated with HIV-infected patients with CD4 counts below 100/µl. In this 
retrospective observational study of medical charts we studied all Dutch patients in whom 
M. genavense was detected between January 2002 and January 2010. Of the 14 patients 
identified, 13 (93%) showed clinical relevant M. genavense disease. All patients with M. 
genavense disease were severely immunocompromised, including HIV-infected patients, 
solid organ transplant recipients, those with chronic steroid use in combination with other 
immune modulating drugs, recipients of chemotherapy for non Hodgkin lymphoma, and 
immunodeficiency syndromes. Two patients had non-disseminated pulmonary M. genavense 
disease. Of the 12 patients treated, eight (75%) showed a favourable outcome. Four patients 
died in this study, three despite treatment for M. genavense disease. We conclude that 
M. genavense is a clinically relevant pathogen in severely immunocompromised patients 
that causes predominantly disseminated disease with serious morbidity and mortality. M. 
genavense is increasingly seen among non-HIV immunocompromised patients. 
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Introduction
Among the nontuberculous mycobacteria (NTM), Mycobacterium genavense has been 
described as a pathogen causing disease with significant morbidity and mortality, especially 
in HIV-infected patients with CD4 counts below 100/µl.1, 2 It was first described by Böttger et 
al. in 1993,3 and retrospectively first  isolated in 1987 from an HIV patient with a disseminated 
infection.4 
In the period after the introduction of antiretroviral therapy (cART) in the late 1990s, 
the epidemiology of M. genavense changed. M. genavense was now acknowledged as 
an opportunistic pathogen in patients with non-HIV immunodeficiencies such as solid 
organ transplant recipients,5-7 patients with both innate and acquired impairment of cell-
mediated immunity, as in some lymphoproliferative malignancies,8 after allogeneic stem cell 
transplantation,9 and patients on immunosuppressive therapy.10-13 The available literature 
focuses only on case reports. Little is known about clinical aspects, treatment and outcome 
in this category of patients. 
M. genavense can be isolated from tap water, healthy birds, and the gastrointestinal tract 
of healthy individuals. Hence, it is important to distinguish contamination and colonization 
from true infection if M. genavense is isolated from a non-sterile source (e.g. the digestive or 
respiratory tract).14-15 The American Thoracic Society (ATS) has published guidelines to assist 
in this distinction.16 The clinical relevance of an NTM species may be quantified by assessing 
the percentage of patients with positive cultures of the respective NTM who meet the ATS 
diagnostic criteria.
We studied the frequency and clinical relevance of M. genavense isolation in the Netherlands, 
using the ATS diagnostic criteria. We focus on clinical aspects, treatment and outcome of 
M. genavense disease.
Methods
The present study is a retrospective observational study of all patients in the Netherlands 
who had M. genavense detected in a clinical sample during the 2002 to 2010 period. Patients 
were identified by reviewing the database of the Dutch National Institute for Public Health 
and the Environment (RIVM) for clinical samples in which M. genavense was detected. The 
RIVM is the national mycobacteria reference laboratory that provides identification and drug 
susceptibility testing for all hospitals in the Netherlands. In addition, all hospitals that perform 
identification of NTM without referral to the RIVM were contacted to include their patients 
with clinical samples in which M. genavense was detected. We reviewed medical records of 
all identified patients in whom M. genavense was detected in the study period. We recorded 
demographic data, clinical data, treatment and outcome. The 2007 ATS diagnostic criteria 
were used to determine clinical relevant infections;16 because M. genavense is extremely 
difficult to culture on routine media, we considered molecular detection of M. genavense 
to equal culture, as the ATS criteria are based on cultures. The ATS diagnostic criteria are 
designed specifically for pulmonary NTM disease. For non-pulmonary infections in this study, 
clinically relevant infection was defined by positive culture or molecular detection of 
M. genavense with clinical signs in accordance with the isolation site and, if applicable, fitting 
radiologic findings. 
To identify NTM, the RIVM used the INNO-LiPA Mycobacteria v2 (Innogenetics, Ghent, 
Belgium) reverse line blot assay was used, which has specific probes for M. genavense. Prior 
to 2004, 16S rDNA gene sequencing was performed by previously published methods,17 after 
ruling out membership of the M. tuberculosis or M. avium complex using the AccuProbe 
assays (GenProbe, San Diego, USA). Similarly, 16S sequencing or INNO-LiPA assays were 
mostly used by the local hospitals. Drug susceptibility testing was not performed. 
The local ethics committee approved the study. 
Results
We identified 14 patients in whom M. genavense was detected in a clinical sample. Thirteen 
(93%) patients met the ATS diagnostic criteria. For 11 patients, M. genavense was detected 
by molecular methods only, in clinical specimens. In three, scanty growth was observed on 
Middlebrook 7H10 solid (n=1) or 7H9 liquid medium (n=2) supplemented with sheep blood 
and Mycobactin J and identified by the INNO-LiPA Mycobacteria v2 assay as M. genavense; 
no growth was observed upon subculture. Seven (54%) patients had M. genavense detected 
in pulmonary samples of whom two had localized M. genavense disease (no other site from 
which M. genavense was detected). In 11 (85%) patients extra-pulmonary samples including 
bone marrow (n=6), blood (2), lymph node (4), liver (2) and stool (3) yielded M. genavense. 
The mean age of the patients at the time of isolation was 54.7 years (range 33-68 years). Of 
the patients with a clinically relevant M. genavense infection, four patients were HIV positive 
and nine patients were immunocompromised due to causes other than HIV infection. 
HIV-infected patients
All four HIV-infected patients presented with disseminated M. genavense disease. The 
mean CD4 count at time of M. genavense isolation was 35/µl (range 10-83). The patients 
mostly reported fever (n=3), malaise (2) and gastro-intestinal symptoms (2). In three patients 
enlarged abdominal lymph nodes were observed. A pulmonary localization of M. genavense 
was proven in one patient who presented with pleural fluid and multifocal nodular lesions on 
chest computed tomography (CT). Treatment was given in all cases and included ethambutol 
and clarithromycin in all patients. In one patient rifampicin was added to the regimen. 
Two patients were cured of M. genavense infection based on negative culture results and 
normalization of radiology results (Table 1). One patient died after 7 months treatment. 
Postmortem examination revealed the cause of death in this patient to be the combination 
of a disseminated M. genavense disease and a cerebral malignancy. One patient is currently 
still on treatment and showed complete resolution of M. genavense related symptoms. As a 
result, a favourable response to treatment was observed in three HIV positive patients.
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Patient Age 
/ 
Sex
Year of 
diagnosis
CD4 
count 
per µl
Detection site Disseminated 
disease
Treatment Outcome
1 33 / 
M
2002 83 Abdominal lymph 
nodes. 
Yes E/Cla 
7.5 years
Cured
2 53 / 
M
2007 52 Liver Yes E/Cla Chronic treated
3 49 / 
M
2002 10 BM, faeces, 
pleural fluid, 
ascites, lung 
biopsy
Yes R/E/Cla
26 months
Cured
4 64 / 
M
2005 10 Faeces. 
Postmortem: 
AFB+ material in:  
BM, spleen, liver 
and lung
Yes E/Cla
several 
months
Died
Cause of death: 
MG disseminated 
disease and 
intracerebral tumor
Table 1: Individual clinical characteristics, treatment and outcome of the HIV positive patients with 
M. genavense disease.
AFB: acid fast bacilli; BM: bone marrow; Cla: clarithromycin; E: ethambutol; Hb: hemoglobin; 
MG: Mycobacterium genavense; R: rifampicine;
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Non-HIV immunocompromised patients
M. genavense was detected in ten non-HIV patients. Nine patients had a clinically 
relevant M. genavense isolation, all of whom were diagnosed with an innate or acquired 
immunodeficiency. Details of the non-HIV patients with a clinically relevant M. genavense 
isolation are summarized in Table 2.
Patient Age/
Sex
underlying 
condition
Immune 
suppression
detection 
site
disseminated 
disease
Treatment outcome
5 55 / 
M
Possible RA Prednisone, 
azathioprine, 
leflunomide
Sputum, 
lung 
biopsy
No R/E/Cla 
18 months
Cured
6 57 / 
M
Sarcoidosis, 
diagnosed 10 
years before first 
isolation
Several years 
prednisone; stopped 
several months 
before first isolation. 
Sputum No R/Cla/
Moxifloxacine 
Resolvement 
of 
complaints. 
AFB 
negative.
Still on 
treatment
7 63 / 
M
NHL Chemotherapy 
(including 
retuximab) 3 
months before first 
isolation
BM Yes R/E/Cla Resolvement 
pancytopenia 
after 3 weeks 
treatment.
Chronic 
treated
8 72/ 
M
Sarcoidosis Prednisone, 
azathioprine,
BM Yes (R)/E/Cla/
Ciprofloxacin
R stopped 
after 1 month 
treatment 
because of 
hepatoxicity
Died, within 
8 weeks after 
MG isolation 
because of 
multi-organ 
failure
9 73 
/ F
Renal 
transplantation 18 
years before first 
isolation
Prednisone, 
mycophebolate 
mofetil
Abdominal 
LN
Yes R/E/H/Z Died, within 
4 weeks after 
MG isolation
10 54 
/ F
Liver 
transplantation 19 
years before first 
MG isolation
Prednisone, 
azathioprine
Blood, 
feces, BM
Yes R/E/Cla 12 
months
Resolvement 
pancytopenia 
after 2 weeks 
treatment
Chronic 
treated R /
Cla
11 43 / 
M
Innate IL-
12 receptor 
deficiency
IL-12 receptor 
deficiency
Sputum, 
cervical 
LN, BM
Yes R/E/Cla Chronic 
treated
12 57 / 
M
Interstitial 
nephritis with 
granuloma
Prednisone, 
cyclophosphamide
Sputum Yes R/E/Cla 
14 months.
Died
13 42 / 
M
Idiopatic CD4+ 
lymphocytopenia
Idiopatic CD4+ 
lymphocytopenia
BM Yes R/E/Cla. Chronic 
treated
Table 2: Individual clinical characteristics, treatment and outcome of the non-HIV immunosuppressed 
patients who presented with M. genavense disease.
AFB: acid fast bacilli;BM: bone marrow; Cla: clarithromycin; E: ethambutol; F: female; H: isoniazide; LN: lymph node; 
M: male; MG: Mycobacterium genavense; NHL: Non-Hodgkin lymphoma; R: rifampicine; Z: pyrazinamide
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Disseminated M. genavense  disease
Seven of nine patients showed disseminated M. genavense disease. Two patients were solid 
organ transplant recipients, the other five patients were immunocompromised due to an 
immunological disorder, immunosuppressive drugs or a haematologic malignancy (Table 
2). Patient number 13, diagnosed with an idiopathic CD4+ T cell lymphocytopenia, also had 
Mycobacterium xenopi  and Mycobacterium simiae isolated from a bronchoalveolar lavage. 
Fever was the most common clinical sign (Table 3). Pancytopenia was seen at the time of M. 
genavense isolation in four cases, all of whom had M. genavense isolated from bone marrow. 
Enlarged para-aortic and mesenteric lymph nodes were the most common abnormalities on 
radiologic examination (n=4), followed by pulmonary dense airspace opacities (2). 
Six patients were treated for M. genavense disease of whom two died; the other patients 
showed a good clinical response and are still, or chronically treated. One patient received a 
treatment for a presumed M. tuberculosis infection and died several weeks after start of this 
treatment.
Symptom or sign dutch patients (n = 7) Literature (n = 9)
Fever 86 67
Weight loss 57 22
Malaise/Fatique 57 22
Productive cough 43 22
Night sweats 29 11
Diarrhea 29 44
Dyspnea 29 0
Abdominal pain 14 44
Vomiting 14 0
Table 3: Frequency (%) of symptoms and signs in non-HIV immune suppressed Dutch and previously 
published cases presenting with disseminated M. genavense disease.5-13
Pulmonary M. genavense disease
Two patients had M. genavense detected repeatedly, but in pulmonary samples only. They had 
no clinical suspicion for other organ involvement of M. genavense (patients 5 and 6 in Table 
2). Patient 6 was free of any immune suppression at time of first M. genavense detection. 
Fever was reported by both patients. Other complaints were dyspnoea, productive cough 
and chest pain. Radiologic examination showed cavitations together with a reticulonodular 
pattern in both patients (Figure 1). Treatment was initiated in both, one was cured and the 
other is still being treated.
Clinically irrelevant detection of M. genavense occured in bronchoalveolar lavage fluid 
obtained in a patient with a community-acquired pneumonia who improved on a course of 
amoxicillin and clavulanic acid. The patient was known to have type 2 diabetes; he had not 
been using immunosuppressive drugs before. No clinical signs or radiologic abnormalities 
suggestive of mycobacterial disease were found during 2 years of follow-up. 
Among the 12 patients treated for M. genavense disease (i.e. with regimens including a 
macrolide, ethambutol and often rifampicin) we recorded a favourable outcome in 75% 
(9/12) of patients (cured, 25% (n=3); chronically treated but with resolution of M. genavense 
related complaints: 50% (n=6)); three died. 
Overall, four patients (4/13, 30%) died in this study because of (disseminated) mycobacterial 
disease: the three treated for M. genavense disease and one who received treatment for 
presumed M. tuberculosis infection (Tables 1 and 2).
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Figure 1: Computed tomography of patient 6. Cavitations are seen in the right upper lobe 
together with a reticulonodular pattern, especially seen in the left lung.
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Discussion
Mycobacterium genavense detection proved to be indicative of clinically relevant disease in 
93% (13/14) of the patients in this study. Disseminated disease was seen in all HIV positive 
patients and in 78% of the non-HIV immunosuppressed patients. To the best of our knowledge, 
we have reported the first two patients with a non-disseminated pulmonary M. genavense 
disease. One of these patients used prednisolone and azathioprine, a drug combination that 
was also used by one of the patients with disseminated disease. The other patient had been 
on systemic steroids and had a pre-existing pulmonary fibrosis with bullae which probably 
predisposed to a pulmonary M. genavense infection. Although little is known about the 
pathogenesis of M. genavense infection, Ehlers and Richter18 showed that immunocompetent 
mice cleared intravenous-injected M. genavense, in contrast to syngeneic gamma-interferon-
gene deficient mice. This observation is in agreement with our study, in which M. genavense 
disseminated disease was only seen in severely immunocompromised patients including HIV-
infected patients, solid organ transplant recipients, chronic steroid use in combination with 
other immune modulating drugs, recipients of chemotherapy for non Hodgkin lymphoma 
and immunodeficiency syndromes. 
Prior to the cART era, M. genavense disease was predominantly seen among HIV-infected 
patients. Tortoli et al. retrospectively reviewed all patients in Italy with M. genavense isolation 
between 1992 and 1996. All 24 patients appeared to be HIV positive with a mean CD4 count 
of 23/µl.1 The epidemiology seems to have changed since the introduction of cART; 71% of 
the patients in this study were HIV negative. This finding is in line with the replacement of HIV 
related M. genavense case reports by non-HIV related M. genavense case reports identified 
in the literature since the publication of Tortoli.5-13 In the Netherlands this epidemiologic shift 
has also been observed since the last literature report of HIV-related M. genavense infection 
was published in this country in 1998.19 
This epidemiologic transition probably reflects the rising number of indications for the use 
of immunosuppressive drugs, and increasing number of solid-organ transplant recipients, 
together with a better life expectancy of this group of patients. Anti-TNF therapy is increasingly 
seen as one of the important immunosuppressive drugs that is giving a higher risk for 
mycobacterial disease.20 21 However, we have not found any patient using anti-TNF therapy. 
No case reports have been described in literature either regarding M. genavense disease 
related to anti-TNF therapy. TNF inhibition alone might not be enough for M. genavense to 
become pathogenic in humans. 
Whether the number of HIV patients presenting with a M. genavense infection is decreasing 
cannot be concluded from our data. However, because M. genavense infection is especially 
observed at CD4 counts below 100/µl, the early initiation of cART in the disease course of an 
HIV patient has certainly influenced its epidemiology; a similar phenomenon has been noted 
for M. avium infections in this group.22  The exact environmental source of M. genavense 
remains unknown. M. genavense has been found in hospital tap water,23 and has been 
isolated with high bacterial load from intestines of apparently healthy birds.24 Furthermore, 
Dumonceau et al.14 reported DNA isolation of M. genavense from macroscopically healthy 
intestinal biopsy samples in five out of nine HIV negative patients. 
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All these patients were free of any clinical sign of infection. This finding supports the 
hypothesis that M. genavense may colonize the gut and disseminate from it when patients 
become immunocompromised.25 If colonization can be found in a high number of healthy 
individuals, as suggested by Dumonceau, then the risk of dissemination from the gut is low 
since M. genavense isolation frequency in the Netherlands (2-4/year) is only a small part of 
the total number of NTM isolated (800/year).26 
Considering the difficulty in culturing M. genavense, underestimation of M. genavense disease 
incidence is likely. Further study is warranted to explore the frequency of M. genavense 
presence in intestines in healthy individuals and factors associated with dissemination. 
Probably, HIV infection with low CD4 counts is an important risk factor for dissemination 
from a colonized gut since the Swiss HIV cohort study found M. genavense in 12.8% of the 
disseminated NTM infections diagnosed between 1990 and 1992.2 
Diagnosis of M. genavense infection remains a challenge for clinicians because of the 
absence of specific symptoms and the difficulties with culturing the organism using standard 
mycobacterial culture methods. In an immunocompromised host, especially with signs of 
disseminated disease (pancytopenia, abdominal lymph nodes), mycobacterial disease 
including M. genavense dissemination has to be considered. 
Nucleic acid amplification techniques are useful to establish a fast and reliable diagnosis. 
Attempts to culture M. genavense are probably best done on solid media (Middlebrook 
7H11) supplemented with blood and charcoal and acidified to pH 6.2 ± 0.2.27
Before cART became available, survival from disseminated M. genavense infection was poor 
and comparable with disseminated Mycobacterium avium complex (MAC) disease with a 
mean survival time of 8,5 months.1, 2, 22 , 28 After cART was introduced, no studies were published 
concerning treatment outcome and survival for M. genavense infected HIV patients. In our 
study, one patient died and one patient is still treated. Probably, as also observed in MAC 
disease, survival for M. genavense improved dramatically because of the combination of cART 
and anti-mycobacterial drugs. However, this has to be confirmed in future (international) 
studies. Little is known about factors associated with mortality in the M. genavense infected 
non-HIV population. Delay in diagnosis and thus treatment, ongoing immune suppression 
and treatment duration are factors to be considered.8, 13 
The optimal treatment regimen for M. genavense disease remains unclear. In vitro susceptibility 
data are limited because of the fastidiousness of the organism. Previous studies, reviewed 
in the ATS Statement, have recorded in vitro susceptibility to rifamycins, streptomycin, 
macrolides, fluoroquinolones and amikacin.16 In our study, all initiated treatments for M. 
genavense consisted of clarithromycin. Ethambutol was added in nine patients, rifampicin in 
eight and moxifloxacin in one patient. 
Current ATS guidelines only state that macrolide based regimens are preferable over other 
regimens; the rifampicin, ethambutol and macrolide regimen advised for M. avium complex 
disease is likely preferable for M. genavense disease, too. Lifelong treatment was given in a 
high percentage of patients and may be indicated when the immunosuppressive condition 
persists; otherwise, therapy may be continued until the patient has been culture-negative for 
12 consecutive months.16
99
M. genavense in the Netherlands
8
In conclusion, M. genavense is an opportunistic pathogen in HIV and non-HIV 
immunocompromised patients, causing mostly disseminated disease with serious morbidity 
and mortality. After the introduction of cART, the epidemiology has changed, with a switch 
to non-HIV immunocompromised patients. The optimal treatment regimen and duration 
is unclear. Since the organism can colonize the gut of healthy individuals, more research is 
needed to determine factors associated with dissemination and disease.
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General discussion
Disease caused by nontuberculous mycobacteria (NTM) is  a growing health problem. There 
is an observed increase in isolation frequency and disease incidence and prevalence, mainly 
in countries with a low incidence of tuberculosis.1-2 However, in contrast to infections with 
M. tuberculosis complex little is known about  NTM including epidemiology, pathogenesis, 
transmission to humans, virulence factors and treatment.
In this thesis, the focus is on epidemiology and clinical relevance of NTM isolation. The 
geographical distribution of NTM is studied from a single time period in chapter 2. The majority 
of the observations made in this study were expected. Still,  some other observations may 
inspire future research on environmental or host factors related to the observed differences. 
Not only isolation rates of NTM species differ between continents, also clinical relevance 
may vary as exampled in the literature review on M. malmoense (chapter 5). In chapter 3, 
the epidemiology of NTM in the Netherlands is studied. An increase in NTM isolation was 
observed, mainly due to M. avium  isolation in  subjects of older age. COPD is an important 
risk factor for NTM pulmonary disease. We have prospectively studied the prevalence of NTM 
in COPD patients with exacerbations not suspected of NTM disease (chapter 4). A surprisingly 
high isolation rate was observed, though only 6% was clinically relevant. Again, higher age 
was significantly related to NTM isolation. This study confirms the importance of the ATS 
diagnostic criteria for NTM disease, and the need for further study on the association between 
COPD and NTM pulmonary disease. Finally, two important species of NTM were studied in 
more detail, both known to show high clinical relevance in patients with local depressed 
immunity (M. malmoense pulmonary disease seen especially in patients with COPD), and 
systemically depressed immunity (M. genavense disseminated disease).
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Epidemiology
Worldwide species distribution
In chapter 2, we describe the worldwide species distribution among NTM from pulmonary 
specimens. There is a difference by region and by country within the regions. M. avium 
complex (MAC) is the most prevalent NTM worldwide; the frequency of isolation of the other 
NTM differs by setting. M. avium predominates in the participating centres in North and 
South America and Europe; M. intracellulare was most frequently isolated in South Africa 
and Australia. In Australia, a significant increase in the isolation and predominance of M. 
intracellulare has been reported before.3 In Japan, M. intracellulare appeared to be the most 
prevalent in the South, M. avium was more prevalent in the North, including Tokyo.4 In our 
study, the data available from Tokyo, Japan, only provided MAC isolation figures without 
subspecies identification. M. intracellulare was the most frequent isolated NTM in a study 
performed in Texas, southern US,5 although this study was not a population-based study. 
Isolation prevalence of the different subspecies within the MAC seems to differ between 
countries and probably even within countries. M. xenopi is an important respiratory tract 
pathogen (ranked third on isolation frequency after MAC and M. gordonae) and increasing in 
different parts of the world as also seen by Martin-Casabona and co-workers.2 On the other 
hand, M. kansasii ranked sixth in our study, which is in agreement with the observed decline 
in isolation frequency in recent years. 
Several arguments may explain the observed differences in worldwide species distribution: 
First, the species distribution may be a reflection of the environmental distribution of NTM. 
Thomson suggested the source of M. intracellulare to be drinking water supplies. This has 
never been systematically studied as a factor in the observed geographical differences in 
MAC subspecies isolation, neither for other NTM species. In a study by Brown-Elliot et al.6 
a hospital and community outbreak of M. porcinum was identified and related to hospital- 
and household drinking supplies. In a 5 year period, M. porcinum isolation from clinical 
specimens was clinical relevant in 46% of the cases. In Australia, M. lentiflavum showed a 
dominant environmental clone. This pathogen, isolated from tap water, was closely related 
to clinical strains based on automated repetitive sequence-based PCR genotyping.7 Wether 
environmental presence (partly) explains the patterns of isolation observed in chapter 2 
remains to be studied. 
Second, geographic differences in NTM isolation can be the result of differences in host factors 
between continents. Among HIV patients, extra-pulmonary MAC disease is the predominant 
NTM disease presentation.8 We studied only pulmonary isolates, so HIV is not a likely 
explanation for the observed geographical differences in MAC isolation. The high isolation 
rate of RGM in Asia can be related to the high tuberculosis incidence in Asian countries. 
Host genetic differences may also account for geographical NTM isolation patterns. Several 
studies from Asian countries report on gene polymorphisms of certain candidate genes for 
mycobacterial infection susceptibility. For example, Koh et al. found an association between 
polymorphisms in the natural resistance-associated macrophage protein 1 gene (Nramp1, 
synonym: slc11A1) and susceptibility to pulmonary NTM disease in Korea. This protein is 
involved in ion transport into the lysosome during phagocytosis of mycobacteria.9 Although 
9
especially patients from whom the RGM M. abscessus was isolated were studied by Koh, it is 
unclear if this Nramp1 polymorphism is associated with the frequently found RGM isolation 
in Asia. In a population-based study from the US among elderly subjects, pulmonary NTM 
disease was mainly prevalent among Asians/Pacific islanders in contrast to whites.10 No 
information was given regarding the NTM species isolated in this study, i.e. whether these 
patient had frequent RGM isolates. Overall, it remains to be studied whether among Asian 
people a certain genetic predisposition accounts for the relatively high RGM isolation. 
Third, the observed geographical differences in species isolation may be explained by 
differences in virulence within a NTM species. As discussed in chapter 5, M. malmoense 
showed high clinical relevance in Northern Europe in contrast to the US. Differences in clinical 
relevance within a NTM species is known for M. kansasii but turned out to be the result of 
different subtypes of M. kansasii with differences in clinical relevance.11 
For M. malmoense, different subtypes have been identified, but without differences in clinical 
relevance. Whole genome sequencing studies will probably reveal intra-species variation 
in mycobacterial virulence factors associated with the observed difference in geographical 
isolation patterns.12-13 
Isolation prevalence
We have shown in chapter 3 that in the Netherlands there is an increase in the total 
number of NTM isolated and a decline in isolation of M. tuberculosis in recent years. The 
first is mainly due to a rise in M. avium isolation in elderly subjects. The increase seems a 
real increase, since it began before improved laboratory techniques were introduced and 
isolation frequencies of the other NTM remained relatively stable during the study period. 
The same increase in NTM isolation, especially MAC, has been observed in other regions 
and countries like Massachusetts, USA,14 Ontario, Canada15 and Australia.3 For many other 
regions worldwide, epidemiological figures of MAC isolation are lacking. Several studies 
have found an increase in overall NTM isolation prevalence16 and disease over time.3, 10, 17, 
18 The increase in NTM disease incidence in the study by Thomson was mainly due to an 
increase in M. intracellulare disease among elderly subjects, especially females with nodular-
bronchiectatic disease.3 A remarkable increase in pulmonary NTM disease prevalence was 
observed among elderly subjects (age > 65 years) in the US among both men and women.10 
In Denmark, a population-based study showed no increase in NTM incidence rates among 
the general population between 1997 and 2007, except in the elderly.19 Parallel to increases 
in NTM isolation from clinical specimens, increases in skin sensitization to NTM antigens have 
been observed; Khan et al. performed a study in which population-representative cohorts 
(1971-1972 vs. 1999-2000) were compared regarding skin sensitization to M. intracellulare.20 
Sensitization increased from 11.2% to 16.6% between the two time periods; age between 20-
39 years, sex, race, birth place, education and occupation were associated with positive skin 
sensitization. This increase is in line with the observed increase in NTM isolation prevalence 
and disease, but it is not clear whether skin sensitization has an association with past or 
future NTM infection. Overall, NTM isolation and disease is increasing in developed countries 
and may not be  fully attributed  to improved laboratory techniques. 
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There are several explanations for the observed increase in isolation prevalence and disease 
rates . As discussed in chapter 3 and shown in other studies, improved awareness among 
clinicians of NTM disease, ageing of the population in combination with growing number 
of COPD patients, increasing numbers of patients with immunosuppressive diseases or 
therapies, and environmental changes are factors to be considered.15, 18, 21-22 
Population-based studies are needed in each continent and country to monitor the change 
in NTM epidemiology over time to reach a better pathophysiological understanding of NTM 
disease and to identify country specific risk groups.
COPD and nontuberculous mycobacteria
The relationship between chronic pulmonary diseases and mycobacterial lung disease was 
known from experiments performed in the 1970s. Silicotic guinea pigs showed progressive 
lung disease when infected with some species of NTM.23 Also from case series in these years, 
reviewed by Emanuel Wolinsky in 1979,24 it became clear that occupational exposure to dust 
(silica), that may cause chronic lung disease, predisposes to NTM lung disease. Nowadays, 
NTM pulmonary disease exists among patients with pre-existing pulmonary disease, especially 
bronchiectasis and COPD.18-19, 21, 25-26 
COPD is the fourth leading cause of death in the world, and further increase in its prevalence 
and mortality can be predicted for the coming decades. Investigation of risk factors related 
to the development of COPD, as well as investigation of cellular and molecular mechanisms 
involved in COPD deterioration, remain an important focus for research as advocated by the 
Global Initiative for COPD.27 Infections (viral and bacterial) may contribute to the pathogenesis 
and disease progression of COPD. In chapter 4, we described the first performed prospective 
study focusing on NTM isolation in COPD patients not suspected of NTM disease. Among all 
the 73 patients included with an acute exacerbation of COPD (AECOPD), 22% of the patients 
had a positive mycobacterial culture. Only higher age was associated with NTM isolation. 
The high NTM isolation rate among the COPD patients in chapter 4 re-emphasizes the 
need for further study on COPD in relation to NTM isolation and disease. The question has 
to be answered whether isolation of a NTM from a patient without clinical signs of NTM 
pulmonary disease impose an increased risk of NTM disease and/or lung function decline 
during follow-up. If NTM are involved in accelerated deterioration of lung function or an 
increased exacerbation frequency in COPD patients, a more vigilant stance or even screening 
may be worthwhile. Furthermore, certain COPD phenotypes or risk factors can probably be 
identified for NTM pulmonary disease.
Retrospective evidence of lung function decline in COPD patients with NTM isolation has 
been found recently.28 In cystic fibrosis (CF), significant more lung function decline have been 
observed in patients from whom mycobacteria are isolated in contrast to patients with no 
mycobacteria isolated.29 Also  deteriorated lung function tests prior to NTM isolation have 
been observed in CF patients.30 Huang et al.,28 found a relationship between NTM isolation 
and more frequent exacerbations of COPD. Still, one may speculate whether the NTM is 
responsible for the increased exacerbation rate and lung function decline in COPD, or that 
the presence of NTM is just a marker of a “bad” COPD phenotype as this maybe also the 
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case in CF related NTM infections.  One may similarly speculate about the observation that 
use of (inhaled) corticosteroids in COPD patients is related to NTM pulmonary disease in 
COPD patients.21 The prescription of inhaled corticosteroids can be related to a specific 
COPD phenotype (for example severe bronchial hyper responsiveness or more pronounced 
bronchiectasis with frequent exacerbations) that again predisposes to NTM presence, instead 
of the hypothesis that the effects of steroids are directly related to NTM presence and/or 
disease in the airways. 
In our study, age was significantly related to NTM isolation in COPD patients. As is discussed 
in chapter 4, higher frequency of co-morbid conditions and use of immunomodulatory drugs 
in the elderly can play a role in this association. This was not addressed in our study. Since 
NTM disease and even colonization are related to increased mortality in the elderly,10 more 
research on etiologic factors in this patient group is needed. For the clinician it is important 
whether screening for NTM in COPD patients is recommendable. In chapter 4 we suggest to 
perform mycobacterial cultures in all patients with bronchiectasis and in COPD patients with 
deteriorating clinical condition despite standard treatment measures. Important questions 
are: is treatment of a single potentially pathogenic NTM isolation necessary in case of an 
increased exacerbation rate? This in the background of increased mortality in patients of older 
age with a single NTM sputum culture.  Or is optimization of COPD treatment sufficient? 
Another argument for screening for NTM disease is the increased use of macrolides in clinical 
practice. Macrolides are prescribed more frequently since it was found that its use prevents 
exacerbations and lung function decline among non-CF bronchiectasis and COPD patients.31, 
32 However, the risk of inducing NTM macrolide resistance as a result of macrolide mono 
therapy with resulting worse treatment outcome in these patients is of concern,33 34 a risk 
that applies especially for MAC, the most common NTM.35 
Our research and that performed by others, shows that COPD predisposes to NTM isolation 
and disease,18, 21 NTM can be detected in sputum of AECOPD patients who are not suspected 
of having NTM disease (chapter 4), higher age is associated with NTM isolation (chapter 4) 
and elder people who have NTM cultured from their sputum have increased mortality.19 
Inhaled corticosteroid use is probably associated with NTM disease,21 and NTM isolation in 
COPD patient is possibly related to increased lung function decline.28
In focus: Mycobacterium malmoense
In this thesis, several aspects of M. malmoense are discussed. First, M. malmoense is a clinically 
relevant NTM in the Netherlands, causing serious pulmonary morbidity with cavitary disease 
as the most common disease presentation. Second, M. malmoense pulmonary disease is 
especially seen among patients with pre-existing COPD. Last, from a literature review we 
observed a rising incidence of M. malmoense isolation especially in Northern Europe together 
with a high clinical relevance in this region. However, in the USA, M. malmoense is rarely 
isolated (chapter 2) and clinical relevance of M. malmoense was observed to be much lower. 
Since pulmonary M. malmoense disease is mostly of the cavitary disease type, treatment for 
a presumed tuberculosis infection is frequently initiated. Thirty per cent of the patients in 
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the study presented in chapter 6 completed a standard 6 months anti-tuberculosis regimen 
for pulmonary M. malmoense disease. Contact tracing studies have been initiated based on 
cavitary disease in a sputum-smear positive patient that turned out to have a pulmonary M. 
malmoense disease; some contacts received 6 months of preventive therapy (chapter 6). In a 
setting where NTM prevalence is higher than tuberculosis, especially in a patient with COPD 
without tuberculosis risk factors, it is important to perform molecular identification techniques 
in order to prevent suboptimal treatment and unnecessary public health measures. 
M. malmoense is an important NTM pathogen in Northern Europe, especially in the United 
Kingdom. In Lothian Scotland, it is the most frequently isolated NTM.36 In our World Map 
study we have confirmed the geographic distribution of M. malmoense (chapter 2). However, 
M. malmoense was in this study also isolated from patients in South Africa, a country where 
M. malmoense isolation from clinical specimens had not been previously reported. It has 
been isolated from the Congo river in the Democratic Republic of Congo.37 Interestingly, M. 
malmoense shows a very low isolation frequency in North America. In a study form Ontario, 
Canada, M. malmoense was not isolated between 1997 and 2003.16 In our World Map study 
we have found five M. malmoense isolates from Canada (compared to a total of 3,443 
NTM isolates from this country) and no isolates from the participating laboratories in the 
US (Portland and Denver). In a previous study from the Unites States, M. malmoense was 
isolated from 73 patients between 1992 and 1994. Most of the isolates in this study were 
from Florida (42/73) and two other southern states.38 In chapter 5 we described that the 
isolation frequency of M. malmoense is on the rise in certain parts of Northern Europe. In 
the Netherlands, however, isolation frequency of M. malmoense remained relatively stable 
between 2002 and 2006 (chapter 6). 
The increase in NTM isolation in the Netherlands, as discussed in chapter 3, was mainly due 
to increase in M. avium isolates. To date, we do not have a clear explanation for the observed 
geographic distribution of M. malmoense, nor do we have regarding differences in clinical 
relevance between Europe and the USA for this organism. Whole genome sequencing of the 
European and US strains can be helpful to identify genetic virulence factors responsible for 
the observed differences in clinical relevance of M. malmoense. Differences in the presence 
of other microbes in the environmental niches can be related to the observed differences 
in virulence within M. malmoense. For example, growth of M. avium within amoeba was 
shown to enhance virulence in a mouse model.39 Host factors will certainly also be important 
in the observed differences in clinical relevance within NTM species (genetic differences, 
differences in habits like smoking, alcohol consumption, dietary factors).25 Interestingly, for 
M. malmoense, polymorphism in the vitamin D receptor have been linked to the susceptibility 
to M. malmoense infection.40
In chapter 7, two patients with a M. malmoense pulmonary infection with a strong 
epidemiological link were studied. Human transmission of NTM disease was strongly suspected 
because a smear positive patient was in close contact with an immunocompromised patient. 
However, the results of genetic testing made human transmission even in this case highly 
unlikely. A case of probable NTM transmission was described from a cystic fibrosis clinic in 
the US. A highly drug-resistant M. abscessus, subspecies M. bolletii (former M. massiliense) 
strain was isolated from an index case and 4 other clinic patients within 8 months.41 It was 
hypothesized that the high mycobacterial load in the sputum of the index case may have 
contaminated the clinical environment and facilitated patient-to-patient transmission. High 
mortality was observed in the patients: three of the 5 infected patients died, the index case 
after lung transplantation. Very recently, a retrospective cohort study from a cystic fibrosis 
centre strongly suggested NTM transmission between cystic fibrosis patients. More study 
is necessary to prove that NTM human transmission may occur, especially in cystic fibrosis 
patients. Retrospective analysis of genotypic results are needed to further study probable 
human transmission of NTM, especially among cystic fibrosis patients, but also in COPD 
patients. The important question then is how this (indirect?) transmission can be prevented.
In focus: Mycobacterium genavense
 
In chapter 8, a retrospective medical file study is described on infections by M. genavense. 
All Dutch patients were studied from whom M. genavense was isolated between 2002 
and 2010. M. genavense were clinical relevant in 93% of the patients. All patients with M. 
genavense disease were severely immunocompromised, including HIV-infected patients 
(CD4 count generally below 100/ul), solid organ transplant recipients, patients treated with 
immune modulating drugs, and patients with immunodeficiency syndromes. M. genavense 
disseminated disease is the most common disease presentation. The clinical presentation 
of disseminated disease is comparable between HIV patients and patients with an impaired 
immunity of other cause,42 and includes fever, weight loss, abdominal pain, diarrhoea, 
and pulmonary symptoms. Abdominal lymph nodes are frequently found in disseminated 
M. genavense disease. Due to difficulty in culturing M. genavense, the diagnosis of M. 
genavense disease is a challenge for clinicians; in an immunocompromised patient with signs 
of disseminated disease, mycobacterial disease including M. genavense dissemination has 
to be considered. Molecular detection techniques have to be used to establish a fast and 
reliable diagnosis.
M. genavense was first described as an opportunistic pathogen in HIV infected patients 
with low CD4 counts. Among HIV patients with disseminated NTM disease, M. genavense 
is isolated in 4-13% of the cases.43-46 As discussed in chapter 8, the introduction of anti-
retroviral therapy has changed the epidemiology of M. genavense dramatically. Patients 
on drugs to prevent rejection after a solid organ transplant are now among the most 
frequently found case-reports in the literature. Interestingly, disseminated M. genavense in 
this patient group can be found years after transplantation: 18 and 19 years after renal and 
liver transplantation respectively in the patients presented in chapter 8, a mean duration 
of 33 months in 3 patients in case series from France,42 and in other case-reports.47-49 NTM 
infections that specifically occur months after starting immunosuppressive drugs are also 
seen among patients who use anti-tumor necrosis factor-α (anti-TNF-α) therapy.50-52 This long 
interval between the start of immunosuppressive drug and development of active infection is 
in contrast to tuberculosis for which a median interval of 12 weeks is observed.53 Probably the 
absence of a latent disease state for NTM, in contrast to tuberculosis is an explanation for this 
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observation. Although patients are on generally three different immunosuppressive drugs 
and thus severely immunocompromised, M. genavense disease is also reported in patients 
with sarcoidosis treated only with prednisone as the patient 8 in chapter 8, and in other case 
reports.54-55 It remains unclear whether the immune reaction in sarcoidosis in combination 
with steroids predisposes to M. genavense disease, or the M. genavense infection was 
actually the cause of the observed granulomateous reaction in at least some patients.56 
Furthermore, the M. genavense infection can just be the result of another coexistent (innate) 
immune disorder in these patient. In chapter 8, we identified a patient with an IL-12 receptor 
deficiency and a patient with an idiopatic CD4 lymphcytopenia as the underlying disorder 
in the disseminated M. genavense infection. Some reports describe M. genavense patients 
with inherited disorders in the IL-12 / IFNy pathway (also called the Mendelian susceptibility 
to mycobacterial disease; MSMD) directly responsible for the disseminated M. genavense 
disease,57 but in some immunesuppressive drugs still seem to be necessary to trigger M. 
genavense disease in this category of patients.58 Anti-TNF-α therapy is not found in case series 
and case reports as a possible cause of M. genavense disease.22 Probably, TNF- α inhibition 
is not enough to promote M. genavense disease but defects in IL-12/IFN-y pathway that 
also result in diminished TNF- α production together with inhibition of various cytokines and 
chemokines do.59
Althought the treatment of M. genavense typically includes a macrolide, rifampicin and 
ethambutol (chapter 8),42 the optimal treatment has still to be established. Besides anti-
mycobacterial therapy, reducing the dosage of immunosuppressive drugs and/or substitution 
of cytokines/chemokines like IFN-y have to be considered given the important role of the 
immune depressed state favouring M. genavense disease.
Clinical relevance of NTM
M. malmoense and M. genavense isolation in the Netherlands is clinically relevant in the 
majority of patients (chapter 6 and 8). In line with other studies from Northern Europe, clinical 
relevance of M. malmoense in the Netherlands was over 80% (chapter 6). It is one of the most 
clinical relevant NTM in the Netherlands, causing serious morbidity and mortality, although 
not frequently isolated. The same is true for M. genavense, an even higher clinical relevance 
was found of 93% in the Netherlands for this NTM, also infrequently isolated (chapter 8). 
Besides work presented in this thesis (chapter 5, 6, and 8), van Ingen et al.18 published one of 
the key articles in the field of clinical relevance of NTM isolation. In this retrospective medical 
file review, all patients with a positive NTM isolated were studied to assess clinical relevance. 
Overall, clinical relevance was found to be 25%, but differed significantly by species: for 
some species, clinical relevance rose far over 50% (M. malmoense, M. kansasii, M. szulgai), 
in contrast to some species that showed almost no clinical relevance (M. fortuitum, M. 
intracellulare, M. gordonae). Based on these findings, as suggested by van Ingen, the ATS 
diagnostic criteria should differentiate between species of low and high clinical relevance, 
with less strict criteria to diagnose disease by highly relevant species and stricter criteria 
to be used for species with low clinical relevance.  If criteria are applied less strict it may 
imply for example that one positive M. malmoense culture from a patient without clinical 
symptoms and with radiographic abnormalities that fits NTM disease, justify a much closer 
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observation of the patient or an earlier initiation of treatment after ruling out alternative 
diagnoses. Support for this approach was found by a follow-up study in patients with a single 
positive sputum sample with a potentially pathogenic NTM.60 In the median follow-up time of 
16 months, a NTM pulmonary disease diagnosis was made in 14% of cases. Only patients with 
MAC, M. abscessus, and M. kansasii isolates were included in this study, probably other NTM 
including M. malmoense will show comparable or even higher disease incidence after a single 
NTM sputum culture. The effects of early initiation of treatment versus close observation for 
these patients with a single NTM sputum sample can be addressed in future studies. In clinical 
practice, it is of  greater importance to relate a positive NTM culture to co-morbid conditions. 
M. genavense isolation from a sterile body site, in a patient with an alleged normal immunity 
must trigger further investigation to detect an immunologic disorder. At the other side of the 
spectrum, a single pulmonary M. gordonae isolation in a patient without clinical signs and 
symptoms, and without asthma or COPD will likely be mere contamination. 
Besides NTM virulence and host factors, clinical relevance of a NTM may be hard to assess if 
the organism is highly fastidious, as in the case of M. genavense. This very difficult to culture 
NTM species can be found in a high percentage of patients in intestine of healthy individuals.61 
Considering this M. genavense colonization of the human gut, clinical relevance figures would 
be much lower if culturing the pathogen was less complicated. In that case M. genavense 
will likely also more frequently be found in the respiratory system as a clinical irrelevant 
species, since M. genavense is acquired via the oral route. Furthermore, the presence of 
certain mycobacteria in niches close to humans will influence clinical relevance; lower clinical 
relevance figures will be found for NTM present in a high amount in tap water because of a 
higher change of culturing the NTM from the oral cavity after, for example a mouth rinse. 
Differences in clinical relevance between the species of NTM is not a matter of differences in 
pathogenicity between the species but a matter of differences in host factors, bacteriological 
factors and environmental factors combined. Because of the observed rise in NTM prevalence 
as discussed before together with geographical differences in species isolation (chapter 2) 
and differences in clinical relevance between continents within the same species (chapter 5), 
future studies remain important to monitor NTM epidemiology and clinical relevance.
Future research 
Although the available literature on NTM has increased, NTM are poorly studied. The quality 
of NTM research issues will be greatly improve if NTM isolation becomes legally notifiable, 
or if a laboratory registration system is nationally introduced. The increase in prevalence of 
NTM disease in an ageing population that is increasingly at risk and the high mortality favour 
such measures. Although treatment outcome remains poor, national surveillance projects on 
NTM including central registration of demographic variables and for example postal codes will 
enhance insight into epidemiological factors and NTM transmission from the environment 
and can thus prioritize research. For example, NTM species that show increase in isolation 
in certain areas will trigger research on transmission vectors from the environment in that 
area. 
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Studies on NTM outbreaks are a possible source of knowledge regarding transmission 
vectors. Most of the studies available report on outbreaks of RGM infections. The majority 
describe RGM skin infections related to infected materials or fluids needed for example for 
acupuncture and tattoos.62 Tap water supplies are an important source of NTM transmission 
to humans. Given the high mycobacterial load that can be found in tap water samples and 
shower heads,63-65 transmission from these supplies with frequent exposure is perhaps more 
likely than transmission from a natural environmental source. Future studies on geographical 
distribution of NTM species have to address water supplies as a source of NTM transmission 
and differences between these supplies as probable cause of the observed geographical 
differences, an explanation that has been addressed before.66 Important differences in 
isolation of mycobacteria from piped water supplies have been observed and was in 
accordance with the epidemiology of NTM disease in the studied countries.67 To enhance 
insight in this matter, future reports on NTM isolation from environmental sources as well as 
from human populations should identify all isolates to the species level since the majority of 
population based studies only provide total numbers of NTM isolation.
We still need a better understanding of the important interplay between mycobacterial 
virulence and host factors. Why does NTM cause disease in some, but not all COPD patients 
after exposure to NTM from the (man-made) environment (showering, use of tap water). It 
has been hypothesized that disease is the result of a multifactorial process, in which both 
acquired local immunodeficiency (e.g. COPD), together with variation in for example dosage 
of inhaled steroid use, and deficits of cell mediated immunity have a role. The immunity to 
mycobacteria in humans is largely determined by the interferon- γ / interleukin-12 pathway, 
by which macrophages that capture the mycobacteria activate T lymphocytes to enable 
successful eradication of the invading mycobacteria. Analyses of host genetics may probably 
reveal polymorphisms in the genes that encode the essential proteins of the interferon-γ 
/ interleukin-12 pathway. Among patients presenting with pulmonary NTM disease it was 
recently found that mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene were seen in 36.5% of the patients, significantly different from the 15.6% in an 
age-/sex-matched group.68 Furthermore, these patients were taller and leaner than control 
subjects, with high rates of scoliosis, pectus excavatum and mitral valve prolapse. 
Nodular-bronchiectatic disease was the most prevalent NTM disease type and the patients 
in this study are thus different from the COPD patients presenting more often with cavitating 
NTM disease. Whether this latter group of patients is also harboring a higher incidence of 
CFTR mutations remains to be studied. Other interesting genes that may play a role in NTM 
pulmonary disease susceptibility are natural resistance-associated macrophage protein 1 
gene (Nramp1),9 the major histocompatibility complex class I chain-related A (MICA) gene,69 
mutations in the vitamin D receptor40 and toll-like receptor 2 (TLR-2) mutations70 and have to 
be further studied for a possible role in COPD related NTM disease. 
The important association between COPD and NTM deserve multi-center prospective case-
control studies in order to find out more about NTM isolation and progression to NTM disease 
and accelerated lung function decline in COPD, especially in older subjects. Knowledge about 
risk factors derived from such studies will give insight into preventive strategies.
There is still a gap in knowledge on drug treatment of NTM pulmonary disease. A combination 
of rifampicine (RMP) and ethambutol (EMB) is the only treatment tested for slow growing 
mycobacteria in a randomized clinical trial, in which addition of clarithromycin (CLA) showed 
no clear outcome benefit.71 This is in contrast to studies from the United States, suggesting 
benefit of the addition of clarithromycin.72 Regimens without RMP have been tested but 
received little attention in current guidelines. Clofazimin, EMB and CLA, however, showed 
sputum conversion rates above 80% and this regimen was in general well tolerated.73 The 
clinical effect of the addition of CLA to the standard regime of RMP and EMB in MAC lung 
disease or lung disease caused by other slow growing NTM needs to be studied in more 
trials. Furthermore, potentially less toxic regimens (clofazimin, EMB and CLA) may be tested 
in multi-center clinical trials. Since treatment duration generally exceeds 12 months with 
toxic drugs, patients and NTM disease characteristics that most likely benefit from treatment 
have to be identified. 
Regarding the RGM, M. abscessus is the most frequent encountered NTM; treatment results 
of pulmonary M. abscessus are very poor and have to be improved by further studies including 
clinical trials in CF related M. abscessus lung disease. Potential drug combinations that show 
synergistic results in vitro may be tested in vivo. The combination of amikacin and clofazimine 
showed synergistic effects across some clinical relevant NTM.74 A multi-center clinical trial 
comparing the standard regimen of RMP/EMB with RMP/EMB combined with clofazimine 
and amikacin is needed. These trials have to include analysis of serum drug concentrations 
which can be related to the MICs and patient outcome.
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Summary
In this thesis studies on nontuberculous mycobacteria (NTM) performed by University Center 
of Chronic Diseases (UCCZ) Dekkerswald (part of the Radboud University Nijmegen Medical 
Center) in close conjunction with the National Institute for Public Health and the Environment 
(RIVM) are presented. The focus of the research is epidemiology and clinical relevance of 
NTM.
In chapter 1 a general introduction on NTM is given. NTM are part of the genus Mycobacterium. 
Mycobacterium tuberculosis complex and Mycobacterium leprae are the other two groups 
that are part of the genus Mycobacterium. More than 120 different NTM species have been 
described. In contrast to M. tuberculosis complex and M. leprae, NTM are opportunistic 
pathogens. NTM are not transmitted from man-to-man. NTM are also called environmental 
mycobacteria due to their widespread environmental presence. Because of this environmental 
presence, isolation of mycobacteria from human samples can be related to true infection, 
pseudo-infection and contamination. The American Thoracic Society (ATS) diagnostic criteria 
are used to determine clinical relevance of the isolation. In the 20th century, the first case 
series of pulmonary NTM disease were published, a disease that showed important similarities 
with pulmonary tuberculosis. Several studies have shown a rise in the isolation prevalence 
of -and disease caused by- NTM in recent years. Because of serious morbidity and mortality 
related to NTM disease, together with poor treatment outcome, research on NTM must have 
a high priority.
 
In chapter 2 the focus is on the NTM species distribution in pulmonary samples worldwide 
from a single time period. This snapshot illustrates that the species distribution among NTM 
isolated from pulmonary specimens in the year 2008 differs by region and differs by country 
within this region. For many regions or countries that participated in this study, these are the 
first data covering this topic. Furthermore, this study confirms previously suggested isolation 
patterns of certain mycobacteria. M. malmoense for example is a well known pathogen in 
Northern Europe (see also chapter 4 and 5 of this thesis) which is also shown in this study. 
Also within Mycobacterium avium complex, important differences are observed in worldwide 
isolation. While M. avium is mainly isolated in northern America, M. intracellulare is especially 
isolated in Australia. However, also some previously stated worldwide isolation patterns of 
certain mycobacteria do not hold true based on our study results. The study presented in 
chapter 2 will hopefully guide future research on transmission of NTM from the environment 
to humans.
In chapter 3 the epidemiology of NTM isolation in the Netherlands is discussed. In many 
countries, including the Netherlands, an increase in NTM isolation has been observed. In 
this study we showed that the total number of NTM rose in absolute terms and relative to 
the number of M. tuberculosis isolates. The rise in NTM isolation was mainly caused by a 
sharp increase in M. avium isolation among patients aged >40 years. Although no review 
of clinical charts was performed in this study, based on previous studies, COPD seems to 
be an important factor for this observation. Since our research group showed COPD to be a 
possible risk factor for NTM disease, we studied this in more detail by a prospective cohort 
study in chapter 4 in which the goal was to study the NTM isolation rate among patients 
presenting with an acute exacerbation of COPD. Seventy-three patients were included, 16 
patients turned out to have one or more positive sputum culture yielding a NTM. In our study, 
only higher age was found to be associated with NTM isolation although bronchiectasis and 
steroid use may have predisposed as well. Although 4 patients were found to have two or 
more NTM of the same species isolated, only one patient turned out to have definite NTM 
disease according to the ATS diagnostic criteria. Further study is necessary to confirm our 
findings and to explore the association between COPD, bronchiectasis and pulmonary NTM 
isolation, including follow-up of patients to find more about NTM isolation and progression 
to NTM disease and accelerated lung function decline.
In chapter 5-7 M. malmoense is studied in more detail. Chapter 5 is a literature review 
concerning epidemiology, clinical relevance, and treatment of M. malmoense. Until the mid-
1990s, M. malmoense isolation showed an increase in many countries in Northern Europe; 
outside Northern Europe M. malmoense was hardly described. An interesting difference in 
clinical relevance of M. malmoense isolation was observed in this review between isolates 
from northern Europe and North America: clinical relevance in North America was 10% in 
contrast to over 70% in Northern Europe. Clinically relevant isolation of M. malmoense was 
mainly observed in COPD patients in the studies included. Available data on treatment for 
M. malmoense is discussed.
In chapter 6 the clinical relevance, treatment and outcome of M. malmoense in the 
Netherlands is studied. We reviewed medical records of all patients with a M. malmoense 
isolate between 2002 and 2006, identified via the national mycobacteria reference laboratory 
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RIVM. Fifty-one patients were identified in this retrospective analysis of whom 40 patients 
had a pulmonary M. malmoense isolate. Thirty-two patients (80%) met the ATS diagnostic 
criteria for pulmonary NTM disease. Of all patients with definite pulmonary M. malmoense 
disease, 81% had pre-existing pulmonary diseases. Cavitary lesions were seen in 88% of 
the patients. Eleven patients had an extra-pulmonary isolate of whom 10 had cervicofacial 
lymphadenitis including two elderly patients. None of the patients in this study were found 
to have an underlying immune deficiency like HIV. Adherence to treatment guidelines was 
relatively poor. Some patients were treated for a presumed pulmonary tuberculosis infection. 
A good clinical response to treatment was observed in 70% and 73% of patients treated 
for pulmonary and extrapulmonary disease, respectively. Two pulmonary M. malmoense 
patients with a strong epidemiological link identified in this study are described in more detail 
in chapter 7. Human transmission was suspected because an acid-fast bacilli (AFB) smear 
positive patient who was in close contact with an immunocompromised patient. However, 
using two molecular typing techniques and hsp65 gene sequencing, strains of both patients 
proved unique and thus human transmission was highly unlikely.
Chapter 8 focuses on a M. genavense, a pathogen that has been described especially in 
patients with HIV with CD4 counts below 100/µl. Reviewing the NTM database of the RIVM, the 
infrequently isolated NTM M. genavense was observed to be isolated especially from sterile 
body sites like bone marrow and liver. In the era of successful HIV treatment, we expected a 
change in its epidemiology and etiology which has not been studied in detail before. Thirteen 
out of the 14 patients retrospectively identified had definite M. genavense disease. Four 
patients were HIV-positive, the other patients had mostly disseminated disease because of 
severe immunosuppression. Four patients died in this study, all because of M. genavense 
disseminated disease. The conclusion is made that M. genavense is a clinically relevant 
pathogen in severely immunocompromised patients that causes predominantly disseminated 
disease. M. genavense is increasingly seen among non-HIV immunocompromised patients.
In chapter 9 our studies are discussed in a broader scientific context. Besides epidemiology 
and clinical relevance (the main focus of this thesis) also NTM in relation to COPD is discussed 
in more detail in this chapter. It is stated that research on NTM isolation and disease will be 
greatly improved if a national surveillance on NTM will be introduced. Furthermore, future 
research topics are discussed and include transmission vectors, mycobacterial virulence 
factors and host factors, NTM pathogenesis among COPD patients and treatment. 
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Samenvatting
In dit proefschrift worden studies gepresenteerd op het gebied van nontuberculeuze 
mycobacteriën (NTM), uitgevoerd door het Universitair Centrum voor Chronische Ziekten 
(UCCZ) Dekkerswald (onderdeel van Radboud Universitair Medisch Centrum) in nauwe 
samenwerking met het Rijksinstituut voor Volksgezondheid en Milieu (RIVM). De focus van 
dit onderzoek is epidemiologie en klinische relevantie van NTM.
Hoofdstuk 1 geeft een algemene inleiding op NTM. NTM maken onderdeel uit van het 
genus Mycobacteriën. Naast NTM worden mycobacteriën onderscheiden die vallen onder 
het Mycobacterium tuberculosis complex en Mycobacterium leprae. Er zijn meer dan 130 
verschillende soorten NTM bekend. In tegenstelling tot M. tuberculosis complex en M. leprae 
zijn NTM opportunistische pathogenen. NTM worden voor zover bekend niet van mens op 
mens overgedragen. NTM zijn milieubacteriën, ze komen wijd verspreid in onder andere water 
en grond voor. Omdat NTM in het milieu voorkomen moet een van een patiënt verkregen 
positieve NTM kweek altijd gerelateerd worden aan de kliniek: het verkregen isolaat kan een 
echte infectie betekenen, pseudo-infectie of contaminatie uit het milieu. De door Amerikaanse 
longartsen gepubliceerde diagnostische criteria (American Thoracic Society criteria on NTM 
disease) kunnen worden gebruikt om de klinische relevantie van een verkregen isolaat te 
bepalen. Halverwege de 20e eeuw zijn de eerste patiënten series beschreven waar pulmonale 
NTM ziekte werd vastgesteld. Pulmonale NTM ziekte heeft een vergelijkbare presentatie als 
pulmonale tuberculose. Verschillende onderzoeken hebben inmiddels een stijging laten zien 
van het aantal gevonden NTM isolaten en het aantal bewezen infecties met NTM. Onderzoek 
op het gebied van NTM is gerechtvaardigd op basis van de morbiditeit en mortaliteit die 
gepaard gaat met infecties in combinatie met slechte uitkomsten van behandeling.
Hoofdstuk 2 beschrijft een onderzoek naar het wereldwijd voorkomen van de verschillende 
NTM species in het jaar 2008. Deze snapshot laat zien dat de wereldwijde NTM species 
verdeling in het jaar 2008 verschilt per continent en verschilt per land binnen een continent. 
Voor een aantal landen die data hebben aangeleverd voor deze studie zijn er niet eerder 
epidemiologische data over NTM gepubliceerd. Daarnaast worden eerder waargenomen 
wereldwijde isolatie patronen middels deze studie bevestigd, bijvoorbeeld het specifiek 
frequent voorkomen van M. malmoense in Noord Europa in tegenstelling tot andere 
werelddelen (zie ook hoofdstuk 4 en 5 van dit proefschrift). Ook binnen het Mycobacterium 
avium complex worden verschillen in wereldwijde isolatie waargenomen. M. avium wordt 
voornamelijk geïsoleerd in Noord Amerika, M. intracellulare met name in Australië. Sommige 
uit de literatuur bekende patronen van isolatie van enkele NTM species worden in deze studie 
niet bevestigd. Het onderzoek wat in dit hoofdstuk wordt gepresenteerd zal richting kunnen 
geven aan toekomstig onderzoek naar transmissie vectoren van NTM naar de mens.
In hoofdstuk 3 wordt de epidemiologie van NTM in Nederland bestudeerd. In veel landen, 
inclusief Nederland, wordt de laatste jaren een stijging van het aantal NTM isolaten gevonden. 
In deze studie laten we zien dat het aantal gevonden NTM isolaten in Nederland stijgt in 
verhouding tot het aantal M. tuberculosis isolaten. Deze stijging in isolatiefrequentie werd met 
name bepaald door een scherpe stijging van het aantal gevonden M. avium isolaten onder 
patiënten ouder dan 40 jaar. Hoewel er in deze studie geen klinische gegevens zijn bestudeerd 
lijkt COPD een belangrijke factor hiervoor te zijn. Aangezien onze onderzoeksgroep eerder 
heeft aangetoond dat COPD een mogelijke risicofactor voor NTM pulmonale ziekte is, hebben 
we dit in meer detail bestudeerd in hoofdstuk 4 middels een prospectieve cohort studie. Het 
doel van deze studie was het bestuderen van de prevalentie van NTM isolatie bij patiënten die 
zich presenteren met een acute exacerbatie van COPD. 73 patiënten werden geïncludeerd, 
16 patiënten bleken één of meerdere positieve NTM sputumkweken te hebben. Hoge leeftijd 
was geassocieerd met een positieve NTM kweek. Er werden vier patiënten gevonden die twee 
of meer positieve NTM kweken hadden van hetzelfde species, een daarvan bleek klinisch 
relevant op basis van de ATS diagnostische criteria. Nader onderzoek is geïndiceerd om onze 
bevindingen te bevestigen en om de associatie tussen COPD, bronchiectasiën en pulmonale 
NTM isolatie verder te bestuderen, inclusief de follow-up van patiënten gericht op progressie 
naar pulmonale NTM ziekte en versneld longfunctieverlies.
In hoofdstuk 5-7 wordt M. malmoense nader bestudeerd. Hoofdstuk 5 is een overzicht van 
de literatuur voor wat betreft epidemiologie, klinische relevantie en behandeling van M. 
malmoense. Tot halverwege de jaren 90 werd er een stijging gezien van het aantal gevonden 
M. malmoense isolaten in Noord Europa; buiten Noord Europa werd M. malmoense nauwelijks 
gerapporteerd. Uit studies geïncludeerd in dit overzicht blijkt verder dat isolaten afkomstig 
uit Noord Europa veel vaker klinisch relevant zijn dan isolaten gevonden in Noord Amerika. 
Klinisch relevante isolatie van M. malmoense werd verder met name gevonden in patiënten 
met onderliggend COPD. Beschikbare literatuur over behandeling van M. malmoense wordt 
besproken.
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In hoofdstuk 6 wordt de klinische relevantie, behandeling en uitkomst van M. malmoense 
in Nederland bestudeerd. De medische dossiers van alle patiënten met een positieve 
M. malmoense isolaat die werden geïdentificeerd via het mycobacterieel referentie 
laboratorium van het RIVM tussen 2002 en 2006 werden ingezien. De klinische relevantie, 
behandeling en uitkomst werden geregistreerd. 51 patiënten werden geïdentificeerd in 
deze retrospectieve analyse, 40 patiënten hadden een pulmonale M. malmoense isolaat. 
32 patiënten (80%) voldeden aan de ATS diagnostische criteria voor NTM pulmonale ziekte. 
Van deze patiënten had 81% een pre-existente longziekte. Caviterende afwijkingen werden 
gezien in 88% van de patiënten. 11 patiënten hadden een extra-pulmonaal isolaat waarvan 
10 een cervicale lymfadenitis bleken te hebben, waaronder 2 oudere patiënten. Geen van 
de patiënten in deze studie bleek een onderliggende immuundeficiëntie te hebben zoals 
HIV. Behandelrichtlijnen werden slecht gevolgd. Sommige patiënten werden behandeld 
voor een pulmonale tuberculose infectie. Een goede klinische respons op behandeling werd 
gevonden in 70% en 73% van de patiënten behandeld voor respectievelijk pulmonale en 
een extra-pulmonale ziekte. Twee patiënten met een sterke epidemiologische link in deze 
studie werden nader bestudeerd in hoofdstuk 7. Humane transmissie werd vermoed op 
basis van sputum Ziehl-Neelsen (ZN) positieve patiënt die veelvuldig contact had met een 
immuungecompromiteerde patiënt. Humane transmissie kon echter niet worden bevestigd 
middels moleculaire technieken waaronder de hsp65 gen sequentie techniek.
Hoofdstuk 8 bestudeerd M. genavense, een pathogeen die met name beschreven is in HIV 
patiënten met een CD4-getal beneden de 100/µl. In de database van het RIVM werd gezien 
dat deze weinig frequent gevonden NTM met name geïsoleerd werd uit steriele organen 
zoals lever en beenmerg. In het tijdperk van succesvolle behandeling van HIV verwachtten 
wij een verandering in epidemiologie en etiologie welke niet eerder is bestudeerd. 13 
van de 14 retrospectief geïdentificeerde patiënten met een M. genavense isolaat bleken 
relevante M. genavense ziekte te hebben. Vier patiënten waren HIV-positief, de andere 
patiënten bleken voornamelijk gedissimineerd M. genavense ziekte te hebben op basis 
van een ernstige immuundeficiëntie. Vier patiënten overleden in deze studie op basis van 
gedissimineerde M. genavense ziekte. Geconcludeerd wordt dat M. genavense een klinisch 
relevant pathogeen is in ernstig immuungecompromiteerde patiënten die voornamelijk 
gedissimineerde ziekte veroorzaakt. M. genavense wordt steeds vaker gezien in de non-HIV 
immuungecompromiteerde patiënt.
In hoofdstuk 9 worden onze studies in een breder wetenschappelijk perspectief besproken. 
Naast epidemiologie en klinische relevantie (de belangrijkste focus van dit proefschrift), 
wordt ook NTM in relatie met COPD bediscussieerd in dit hoofdstuk. Er wordt gesteld 
dat onderzoek op het gebied van NTM ziekte verbeterd zal worden als NTM isolatie 
meldingsplichtig gemaakt wordt. Daarnaast worden in dit hoofdstuk onderwerpen voor 
toekomstig onderzoek besproken zoals transmissie vectoren, mycobacteriële virulentie - en 
gastheer factoren, NTM pathogenese in COPD patiënten en behandeling.
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voorzien. Inspirerend om met je van gedachten te wisselen over ons onderzoek. Ik hoop op 
een blijvende samenwerking en niet te vergeten, nog wat vaker gezellige avondjes met die 
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Melanie Wattenberg, van het mycobacteriële laboratorium Dekkerswald en nu Radboud, niet 
alleen heb je mijn enthousiasme voor mycobacteriën doen vergroten, jij was de belangrijkste 
coördinator van de NACHT studie (hoofdstuk 4). Ik wil je heel erg bedanken daarvoor. Ook je 
collega’s Yvonne en Nicole bedankt voor jullie inzet.
Ik ben veel dank verschuldigd aan mijn collega’s in het UCCZ Dekkerswald: Martin, Monique, 
Jeanine, Cecile, Johan, Janet en Jolanda. Geweldig dat ik in de afrondende fase van mijn 
proefschrift van de werkvloer af en toe kon wegblijven om te schrijven! Ook in de periode 
dat ik in opleiding was tot longarts heb ik hier en daar wat tijd mogen besteden aan het 
onderzoek. Mijn collega longartsen i.o. van toen wil ik daarvoor ook bedanken: Annelies, 
Christof, Daan, Esther, Evelien, Giny, Hans, Hester, Jelle, Laura, Mariëlle, Roline, Ruth, Saar, 
Sami en Wai-Yee.
Veel verpleegkundigen en secretaresses van Dekkerswald hebben mij fantastisch geholpen 
bij de NACHT studie (hoofdstuk 4). Annemarie wil ik hier toch speciaal noemen als trekker van 
de NACHT-studie kar op de afdeling. Heel veel dank daarvoor. Femke Cuppen, bedankt voor 
het helpen met de data verzameling. Thy en Claudia, bedankt voor jullie geweldige steun met 
de logistiek om en rond mijn boekje!
Via deze weg wil ik alle longartsen en andere medisch specialisten in Nederland bedanken 
die de inzages in medische dossiers voor het retrospectieve onderzoek mogelijk hebben 
gemaakt.
Suicide Bunnies and friends, hardloopvriendjes, tijd voor een feestje! Gaby, hopelijk houd 
jij ze een beetje bij de les tijdens het officiële gebeuren. Bedankt dat je paranimf wilde zijn! 
Michiel, bedankt dat ik bij je mocht afkijken hoe je moet promoveren (als dat maar goed 
gaat!). Heleen, bedankt voor je steun die je mij gaf in de beginperiode van het onderzoek. 
Tim, Kerim, Alef en Erwin: hopelijk blijf ik voor jullie gewoon de kleine jongen! Mochten we 
ooit nog eens op vakantie gaan, dan zal ik vertellen over mijn proefschrift (die scriptie kennen 
jullie nu wel). Heerlijk zullen jullie slapen! Mark, Jakko en Erik: gelukkig heb ik het met jullie 
vaker over andere dingen. Maar toch ervaar ik de vriendschap met jullie als bijzonder waar 
ik in mijn werk ook veel aan heb! Martijn Nap, geweldige studievriend, ons eerste gesprek 
ging over Jiskefet. Ook al zien we elkaar niet zo heel vaak, gelukkig weten we nog steeds een 
vergelijkbaar niveau te halen!
Lieve papa en mama, zonder jullie steun, altijd en overal, had ik deze streep niet kunnen 
halen. Ik ben jullie heel erg dankbaar. Markus, broer, sorry dat ik je verjaardagsfeestje verpest 
door deze promotie. En Gerlof, broer, bedankt dat je paranimf wilde zijn. 
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